ID   LMNA_HUMAN              Reviewed;         664 AA.
AC   P02545; B4DI32; D3DVB0; D6RAQ3; E7EUI9; P02546; Q5I6Y4; Q5I6Y6; Q5TCJ2;
AC   Q5TCJ3; Q6UYC3; Q969I8; Q96JA2;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   20-MAR-1987, sequence version 1.
DT   28-JUN-2023, entry version 272.
DE   RecName: Full=Prelamin-A/C;
DE   Contains:
DE     RecName: Full=Lamin-A/C;
DE     AltName: Full=70 kDa lamin;
DE     AltName: Full=Renal carcinoma antigen NY-REN-32;
DE   Flags: Precursor;
GN   Name=LMNA; Synonyms=LMN1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS A AND C).
RX   PubMed=3453101; DOI=10.1038/319463a0;
RA   McKeon F.D., Kirschner M.W., Caput D.;
RT   "Homologies in both primary and secondary structure between nuclear
RT   envelope and intermediate filament proteins.";
RL   Nature 319:463-468(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS A AND C), AND PROTEIN SEQUENCE OF
RP   583-644.
RX   PubMed=3462705; DOI=10.1073/pnas.83.17.6450;
RA   Fisher D.Z., Chaudhary N., Blobel G.;
RT   "cDNA sequencing of nuclear lamins A and C reveals primary and secondary
RT   structural homology to intermediate filament proteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:6450-6454(1986).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A), SUBCELLULAR LOCATION (ISOFORM C),
RP   VARIANTS CMD1A TRP-190; GLY-192 AND SER-541, AND CHARACTERIZATION OF
RP   VARIANTS CMD1A GLY-192 AND SER-541.
RX   PubMed=16061563; DOI=10.1136/jmg.2004.023283;
RA   Sylvius N., Bilinska Z.T., Veinot J.P., Fidzianska A., Bolongo P.M.,
RA   Poon S., McKeown P., Davies R.A., Chan K.-L., Tang A.S.L., Dyack S.,
RA   Grzybowski J., Ruzyllo W., McBride H., Tesson F.;
RT   "In vivo and in vitro examination of the functional significances of novel
RT   lamin gene mutations in heart failure patients.";
RL   J. Med. Genet. 42:639-647(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 6).
RA   Csoka A.B.;
RT   "The progerin allele of lamin A disrupts chromatin organization.";
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Corpus callosum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS A AND C).
RC   TISSUE=Kidney, Lung, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   PROTEIN SEQUENCE OF 12-25; 29-90; 102-117; 120-166; 172-189; 197-216;
RP   226-233; 241-260; 281-316; 320-329; 352-386; 440-453; 456-482; 472-482;
RP   516-542; 585-624 AND 628-644, PHOSPHORYLATION AT SER-22, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY.
RC   TISSUE=Ovarian carcinoma;
RA   Bienvenut W.V., Lilla S., von Kriegsheim A., Lempens A., Kolch W.,
RA   Norman J.C.;
RL   Submitted (OCT-2009) to UniProtKB.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 375-664 (ISOFORM ADELTA10).
RC   TISSUE=Colon;
RX   PubMed=8621584; DOI=10.1074/jbc.271.16.9249;
RA   Machiels B.M., Zorenc A.H., Endert J.M., Kuijpers H.J., van Eys G.J.,
RA   Ramaekers F.C., Broers J.L.;
RT   "An alternative splicing product of the lamin A/C gene lacks exon 10.";
RL   J. Biol. Chem. 271:9249-9253(1996).
RN   [11]
RP   PROTEOLYTIC CLEAVAGE, ISOPRENYLATION AT CYS-661, AND METHYLATION AT
RP   CYS-661.
RX   PubMed=8175923; DOI=10.1242/jcs.107.1.61;
RA   Sinensky M., Fantle K., Trujillo M., McLain T., Kupfer A., Dalton M.;
RT   "The processing pathway of prelamin A.";
RL   J. Cell Sci. 107:61-67(1994).
RN   [12]
RP   PROTEOLYTIC CLEAVAGE, ISOPRENYLATION AT CYS-661, AND METHYLATION AT
RP   CYS-661.
RX   PubMed=9030603; DOI=10.1074/jbc.272.8.5298;
RA   Kilic F., Dalton M.B., Burrell S.K., Mayer J.P., Patterson S.D.,
RA   Sinensky M.;
RT   "In vitro assay and characterization of the farnesylation-dependent
RT   prelamin A endoprotease.";
RL   J. Biol. Chem. 272:5298-5304(1997).
RN   [13]
RP   IDENTIFICATION AS A RENAL CANCER ANTIGEN.
RC   TISSUE=Renal cell carcinoma;
RX   PubMed=10508479;
RX   DOI=10.1002/(sici)1097-0215(19991112)83:4<456::aid-ijc4>3.0.co;2-5;
RA   Scanlan M.J., Gordan J.D., Williamson B., Stockert E., Bander N.H.,
RA   Jongeneel C.V., Gure A.O., Jaeger D., Jaeger E., Knuth A., Chen Y.-T.,
RA   Old L.J.;
RT   "Antigens recognized by autologous antibody in patients with renal-cell
RT   carcinoma.";
RL   Int. J. Cancer 83:456-464(1999).
RN   [14]
RP   INTERACTION WITH NARF, AND MUTAGENESIS OF CYS-661.
RX   PubMed=10514485; DOI=10.1074/jbc.274.42.30008;
RA   Barton R.M., Worman H.J.;
RT   "Prenylated prelamin A interacts with Narf, a novel nuclear protein.";
RL   J. Biol. Chem. 274:30008-30018(1999).
RN   [15]
RP   INTERACTION WITH TMPO-ALPHA AND RB1.
RX   PubMed=12475961; DOI=10.1091/mbc.e02-07-0450;
RA   Markiewicz E., Dechat T., Foisner R., Quinlan R.A., Hutchison C.J.;
RT   "Lamin A/C binding protein LAP2alpha is required for nuclear anchorage of
RT   retinoblastoma protein.";
RL   Mol. Biol. Cell 13:4401-4413(2002).
RN   [16]
RP   ALTERNATIVE SPLICING, INVOLVEMENT IN HGPS (ISOFORM 6), AND VARIANTS HGPS
RP   LYS-145 AND SER-608.
RX   PubMed=12714972; DOI=10.1038/nature01629;
RA   Eriksson M., Brown W.T., Gordon L.B., Glynn M.W., Singer J., Scott L.,
RA   Erdos M.R., Robbins C.M., Moses T.Y., Berglund P., Dutra A., Pak E.,
RA   Durkin S., Csoka A.B., Boehnke M., Glover T.W., Collins F.S.;
RT   "Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford
RT   progeria syndrome.";
RL   Nature 423:293-298(2003).
RN   [17]
RP   INTERACTION WITH LEMD2 (ISOFORM C).
RX   PubMed=16339967; DOI=10.1242/jcs.02701;
RA   Brachner A., Reipert S., Foisner R., Gotzmann J.;
RT   "LEM2 is a novel MAN1-related inner nuclear membrane protein associated
RT   with A-type lamins.";
RL   J. Cell Sci. 118:5797-5810(2005).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-277, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-19; SER-22; SER-390; SER-392;
RP   SER-395; SER-628; SER-632 AND SER-636, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-628, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17924679; DOI=10.1021/pr070152u;
RA   Yu L.R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D.;
RT   "Improved titanium dioxide enrichment of phosphopeptides from HeLa cells
RT   and high confident phosphopeptide identification by cross-validation of
RT   MS/MS and MS/MS/MS spectra.";
RL   J. Proteome Res. 6:4150-4162(2007).
RN   [21]
RP   SUBCELLULAR LOCATION, SUMOYLATION AT LYS-201, MUTAGENESIS OF LYS-201, AND
RP   CHARACTERIZATION OF VARIANTS CMD1A GLY-203 AND LYS-203.
RX   PubMed=18606848; DOI=10.1083/jcb.200712124;
RA   Zhang Y.Q., Sarge K.D.;
RT   "Sumoylation regulates lamin A function and is lost in lamin A mutants
RT   associated with familial cardiomyopathies.";
RL   J. Cell Biol. 182:35-39(2008).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-628, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-632, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-12; SER-18; THR-19; SER-22;
RP   SER-301; SER-390; SER-392; SER-395; SER-458; SER-628; SER-632; SER-636 AND
RP   SER-652, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [26]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH EMD.
RX   PubMed=19323649; DOI=10.1042/bc20080175;
RA   Capanni C., Del Coco R., Mattioli E., Camozzi D., Columbaro M., Schena E.,
RA   Merlini L., Squarzoni S., Maraldi N.M., Lattanzi G.;
RT   "Emerin-prelamin A interplay in human fibroblasts.";
RL   Biol. Cell 101:541-554(2009).
RN   [27]
RP   SUBCELLULAR LOCATION, AND CHARACTERIZATION OF VARIANTS FPLD2 CYS-439 AND
RP   TRP-482.
RX   PubMed=19220582; DOI=10.1111/j.1582-4934.2009.00690.x;
RA   Verstraeten V.L., Caputo S., van Steensel M.A., Duband-Goulet I.,
RA   Zinn-Justin S., Kamps M., Kuijpers H.J., Ostlund C., Worman H.J.,
RA   Briede J.J., Le Dour C., Marcelis C.L., van Geel M., Steijlen P.M.,
RA   van den Wijngaard A., Ramaekers F.C., Broers J.L.;
RT   "The R439C mutation in LMNA causes lamin oligomerization and susceptibility
RT   to oxidative stress.";
RL   J. Cell. Mol. Med. 13:959-971(2009).
RN   [28]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-108; LYS-270; LYS-311 AND
RP   LYS-450, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [29]
RP   FUNCTION.
RX   PubMed=20079404; DOI=10.1016/j.bbagen.2010.01.002;
RA   De Vos W.H., Houben F., Hoebe R.A., Hennekam R., van Engelen B.,
RA   Manders E.M., Ramaekers F.C., Broers J.L., Van Oostveldt P.;
RT   "Increased plasticity of the nuclear envelope and hypermobility of
RT   telomeres due to the loss of A-type lamins.";
RL   Biochim. Biophys. Acta 1800:448-458(2010).
RN   [30]
RP   SUBCELLULAR LOCATION, AND VARIANTS CMD1A LEU-89; PRO-101; PRO-166; GLN-190;
RP   LYS-203; SER-210; PRO-215; THR-318; HIS-388; CYS-399 AND HIS-471.
RX   PubMed=20160190; DOI=10.1161/circgenetics.109.905422;
RA   Cowan J., Li D., Gonzalez-Quintana J., Morales A., Hershberger R.E.;
RT   "Morphological analysis of 13 LMNA variants identified in a cohort of 324
RT   unrelated patients with idiopathic or familial dilated cardiomyopathy.";
RL   Circ. Cardiovasc. Genet. 3:6-14(2010).
RN   [31]
RP   FUNCTION, PROTEOLYTIC PROCESSING, AND TISSUE SPECIFICITY.
RX   PubMed=20458013; DOI=10.1161/circulationaha.109.902056;
RA   Ragnauth C.D., Warren D.T., Liu Y., McNair R., Tajsic T., Figg N.,
RA   Shroff R., Skepper J., Shanahan C.M.;
RT   "Prelamin A acts to accelerate smooth muscle cell senescence and is a novel
RT   biomarker of human vascular aging.";
RL   Circulation 121:2200-2210(2010).
RN   [32]
RP   INTERACTION WITH SUN1, CHARACTERIZATION OF VARIANTS EDMD2 PRO-527 AND
RP   PRO-530, AND CHARACTERIZATION OF VARIANT HGPS SER-608.
RX   PubMed=19933576; DOI=10.1074/jbc.m109.071910;
RA   Haque F., Mazzeo D., Patel J.T., Smallwood D.T., Ellis J.A., Shanahan C.M.,
RA   Shackleton S.;
RT   "Mammalian SUN protein interaction networks at the inner nuclear membrane
RT   and their role in laminopathy disease processes.";
RL   J. Biol. Chem. 285:3487-3498(2010).
RN   [33]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, PHOSPHORYLATION [LARGE SCALE
RP   ANALYSIS] AT THR-3; SER-12; THR-19; SER-22; SER-212; SER-277; SER-301;
RP   SER-390; SER-392; SER-395; SER-404; SER-414; SER-431; SER-458; SER-463;
RP   THR-505; SER-628; SER-632; SER-636 AND SER-652, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [35]
RP   INTERACTION WITH MLIP.
RX   PubMed=21498514; DOI=10.1074/jbc.m110.165548;
RA   Ahmady E., Deeke S.A., Rabaa S., Kouri L., Kenney L., Stewart A.F.,
RA   Burgon P.G.;
RT   "Identification of a novel muscle enriched A-type Lamin interacting protein
RT   (MLIP).";
RL   J. Biol. Chem. 286:19702-19713(2011).
RN   [36]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-390; SER-392; SER-404;
RP   SER-414; SER-458 AND SER-636, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [37]
RP   MUTAGENESIS OF ARG-644; LEU-647; LEU-648; ASN-650 AND CYS-661, AND
RP   CHARACTERIZATION OF VARIANT HGPS CYS-644.
RX   PubMed=22355414; DOI=10.1371/journal.pone.0032120;
RA   Barrowman J., Hamblet C., Kane M.S., Michaelis S.;
RT   "Requirements for efficient proteolytic cleavage of prelamin A by
RT   ZMPSTE24.";
RL   PLoS ONE 7:E32120-E32120(2012).
RN   [38]
RP   FUNCTION, SUBCELLULAR LOCATION, INVOLVEMENT IN HGPS, VARIANT HGPS GLY-300,
RP   AND CHARACTERIZATION OF VARIANT HGPS GLY-300.
RX   PubMed=23666920; DOI=10.1002/ajmg.a.35971;
RA   Kane M.S., Lindsay M.E., Judge D.P., Barrowman J., Ap Rhys C., Simonson L.,
RA   Dietz H.C., Michaelis S.;
RT   "LMNA-associated cardiocutaneous progeria: An inherited autosomal dominant
RT   premature aging syndrome with late onset.";
RL   Am. J. Med. Genet. A 161:1599-1611(2013).
RN   [39]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-12; THR-19; SER-22; SER-51;
RP   SER-66; SER-71; SER-107; SER-212; SER-301; SER-390; SER-392; SER-398;
RP   SER-429; SER-458; SER-463; SER-533; SER-613; SER-619; SER-628; SER-632 AND
RP   SER-636, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [40]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH SUV39H1.
RX   PubMed=23695662; DOI=10.1038/ncomms2885;
RA   Liu B., Wang Z., Zhang L., Ghosh S., Zheng H., Zhou Z.;
RT   "Depleting the methyltransferase Suv39h1 improves DNA repair and extends
RT   lifespan in a progeria mouse model.";
RL   Nat. Commun. 4:1868-1868(2013).
RN   [41]
RP   INTERACTION WITH DMPK.
RX   PubMed=21949239; DOI=10.1074/jbc.m111.241455;
RA   Harmon E.B., Harmon M.L., Larsen T.D., Yang J., Glasford J.W.,
RA   Perryman M.B.;
RT   "Myotonic dystrophy protein kinase is critical for nuclear envelope
RT   integrity.";
RL   J. Biol. Chem. 286:40296-40306(2011).
RN   [42]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-12; THR-19; SER-22; SER-212;
RP   SER-301; SER-307; SER-390; SER-395; SER-403; SER-404; SER-414; SER-458;
RP   SER-463; SER-612 AND SER-636, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [43]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-97; LYS-208; LYS-233; LYS-311;
RP   LYS-378; LYS-417 AND LYS-420, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [44]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-233 AND LYS-597, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [45]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-97; LYS-311; LYS-378 AND LYS-420,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [46]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-233; LYS-260; LYS-270; LYS-378;
RP   LYS-417 AND LYS-420, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.o114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to replication
RT   stress reveals novel small ubiquitin-like modified target proteins and
RT   acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [47]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [48]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-32; LYS-97; LYS-171; LYS-201;
RP   LYS-208; LYS-219; LYS-233; LYS-260; LYS-270; LYS-311; LYS-366; LYS-378;
RP   LYS-417; LYS-420; LYS-450; LYS-470; LYS-486 AND LYS-597, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [49]
RP   INTERACTION WITH ITSN1 ISOFORM 2, AND SUBCELLULAR LOCATION.
RX   PubMed=29599122; DOI=10.1042/bcj20170897;
RA   Alvisi G., Paolini L., Contarini A., Zambarda C., Di Antonio V.,
RA   Colosini A., Mercandelli N., Timmoneri M., Palu G., Caimi L., Ricotta D.,
RA   Radeghieri A.;
RT   "Intersectin goes nuclear: secret life of an endocytic protein.";
RL   Biochem. J. 475:1455-1472(2018).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 435-552.
RX   PubMed=11901143; DOI=10.1074/jbc.c200038200;
RA   Dhe-Paganon S., Werner E.D., Chi Y.I., Shoelson S.E.;
RT   "Structure of the globular tail of nuclear lamin.";
RL   J. Biol. Chem. 277:17381-17384(2002).
RN   [51]
RP   STRUCTURE BY NMR OF 428-549.
RX   PubMed=12057196; DOI=10.1016/s0969-2126(02)00777-3;
RA   Krimm I., Ostlund C., Gilquin B., Couprie J., Hossenlopp P., Mornon J.-P.,
RA   Bonne G., Courvalin J.-C., Worman H.J., Zinn-Justin S.;
RT   "The Ig-like structure of the C-terminal domain of lamin A/C, mutated in
RT   muscular dystrophies, cardiomyopathy, and partial lipodystrophy.";
RL   Structure 10:811-823(2002).
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 305-387, AND SUBUNIT.
RX   PubMed=15476822; DOI=10.1016/j.jmb.2004.08.093;
RA   Strelkov S.V., Schumacher J., Burkhard P., Aebi U., Herrmann H.;
RT   "Crystal structure of the human lamin A coil 2B dimer: implications for the
RT   head-to-tail association of nuclear lamins.";
RL   J. Mol. Biol. 343:1067-1080(2004).
RN   [53]
RP   VARIANTS EDMD2 TRP-453; PRO-527 AND PRO-530, FUNCTION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=10080180; DOI=10.1038/6799;
RA   Bonne G., Di Barletta M.R., Varnous S., Becane H.-M., Hammouda E.-H.,
RA   Merlini L., Muntoni F., Greenberg C.R., Gary F., Urtizberea J.-A.,
RA   Duboc D., Fardeau M., Toniolo D., Schwartz K.;
RT   "Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-
RT   Dreifuss muscular dystrophy.";
RL   Nat. Genet. 21:285-288(1999).
RN   [54]
RP   VARIANTS CMD1A GLY-60; ARG-85; LYS-195 AND GLY-203, AND FUNCTION.
RX   PubMed=10580070; DOI=10.1056/nejm199912023412302;
RA   Fatkin D., MacRae C., Sasaki T., Wolff M.R., Porcu M., Frenneaux M.,
RA   Atherton J., Vidaillet H.J. Jr., Spudich S., De Girolami U., Seidman J.G.,
RA   Seidman C.E.;
RT   "Missense mutations in the rod domain of the lamin A/C gene as causes of
RT   dilated cardiomyopathy and conduction-system disease.";
RL   N. Engl. J. Med. 341:1715-1724(1999).
RN   [55]
RP   VARIANTS FPLD2 ASP-465; GLN-482; TRP-482 AND HIS-582.
RX   PubMed=10739751; DOI=10.1086/302836;
RA   Speckman R.A., Garg A., Du F., Bennett L., Veile R., Arioglu E.,
RA   Taylor S.I., Lovett M., Bowcock A.M.;
RT   "Mutational and haplotype analyses of families with familial partial
RT   lipodystrophy (Dunnigan variety) reveal recurrent missense mutations in the
RT   globular C-terminal domain of lamin A/C.";
RL   Am. J. Hum. Genet. 66:1192-1198(2000).
RN   [56]
RP   ERRATUM OF PUBMED:10739751.
RA   Speckman R.A., Garg A., Du F., Bennett L., Veile R., Arioglu E.,
RA   Taylor S.I., Lovett M., Bowcock A.M.;
RL   Am. J. Hum. Genet. 67:775-775(2000).
RN   [57]
RP   VARIANTS EDMD2 TYR-222; GLN-249; GLN-336; TRP-453; THR-469; PRO-527 AND
RP   LYS-528.
RX   PubMed=10739764; DOI=10.1086/302869;
RA   Raffaele di Barletta M., Ricci E., Galluzzi G., Tonali P., Mora M.,
RA   Morandi L., Romorini A., Voit T., Orstavik K.H., Merlini L., Trevisan C.,
RA   Biancalana V., Housmanowa-Petrusewicz I., Bione S., Ricotti R.,
RA   Schwartz K., Bonne G., Toniolo D.;
RT   "Different mutations in the LMNA gene cause autosomal dominant and
RT   autosomal recessive Emery-Dreifuss muscular dystrophy.";
RL   Am. J. Hum. Genet. 66:1407-1412(2000).
RN   [58]
RP   VARIANTS EDMD2 CYS-45; PRO-50; SER-63; GLU-112 DEL; PRO-222; GLU-232;
RP   GLN-249; LYS-261 DEL; PRO-294; LYS-358; LYS-371; LYS-386; TRP-453; LYS-456;
RP   SER-520; PRO-527 AND LYS-528.
RX   PubMed=10939567;
RX   DOI=10.1002/1531-8249(200008)48:2<170::aid-ana6>3.3.co;2-a;
RA   Bonne G., Mercuri E., Muchir A., Urtizberea A., Becane H.M., Recan D.,
RA   Merlini L., Wehnert M., Boor R., Reuner U., Vorgerd M., Wicklein E.M.,
RA   Eymard B., Duboc D., Penisson-Besnier I., Cuisset J.M., Ferrer X.,
RA   Desguerre I., Lacombe D., Bushby K., Pollitt C., Toniolo D., Fardeau M.,
RA   Schwartz K., Muntoni F.;
RT   "Clinical and molecular genetic spectrum of autosomal dominant Emery-
RT   Dreifuss muscular dystrophy due to mutations of the lamin A/C gene.";
RL   Ann. Neurol. 48:170-180(2000).
RN   [59]
RP   VARIANT FPLD2 GLN-482, AND FUNCTION.
RX   PubMed=10587585; DOI=10.1093/hmg/9.1.109;
RA   Cao H., Hegele R.A.;
RT   "Nuclear lamin A/C R482Q mutation in Canadian kindreds with Dunnigan-type
RT   familial partial lipodystrophy.";
RL   Hum. Mol. Genet. 9:109-112(2000).
RN   [60]
RP   VARIANTS EDMD2 LYS-208 DEL AND HIS-377, AND FUNCTION.
RX   PubMed=10814726; DOI=10.1093/hmg/9.9.1453;
RA   Muchir A., Bonne G., van der Kooi A.J., van Meegen M., Baas F.,
RA   Bolhuis P.A., de Visser M., Schwartz K.;
RT   "Identification of mutations in the gene encoding lamins A/C in autosomal
RT   dominant limb girdle muscular dystrophy with atrioventricular conduction
RT   disturbances (LGMD1B).";
RL   Hum. Mol. Genet. 9:1453-1459(2000).
RN   [61]
RP   VARIANTS FPLD2 LEU-482 AND TRP-482.
RX   PubMed=10655060; DOI=10.1038/72807;
RA   Shackleton S., Lloyd D.J., Jackson S.N.J., Evans R., Niermeijer M.F.,
RA   Singh B.M., Schmidt H., Brabant G., Kumar S., Durrington P.N., Gregory S.,
RA   O'Rahilly S., Trembath R.C.;
RT   "LMNA, encoding lamin A/C, is mutated in partial lipodystrophy.";
RL   Nat. Genet. 24:153-156(2000).
RN   [62]
RP   VARIANTS EDMD2 PRO-150 AND LYS-261 DEL.
RX   PubMed=10908904; DOI=10.1212/wnl.55.2.275;
RA   Felice K.J., Schwartz R.C., Brown C.A., Leicher C.R., Grunnet M.L.;
RT   "Autosomal dominant Emery-Dreifuss dystrophy due to mutations in rod domain
RT   of the lamin A/C gene.";
RL   Neurology 55:275-280(2000).
RN   [63]
RP   VARIANTS EDMD2 PRO-25; THR-43; SER-50; PRO-133; 196-ARG--THR-199 DELINS
RP   SER; GLN-249; LYS-261 DEL; LYS-358; TRP-453; ILE-456; PRO-527 AND HIS-624.
RX   PubMed=11503164; DOI=10.1002/ajmg.1463;
RA   Brown C.A., Lanning R.W., McKinney K.Q., Salvino A.R., Cherniske E.,
RA   Crowe C.A., Darras B.T., Gominak S., Greenberg C.R., Grosmann C.,
RA   Heydemann P., Mendell J.R., Pober B.R., Sasaki T., Shapiro F.,
RA   Simpson D.A., Suchowersky O., Spence J.E.;
RT   "Novel and recurrent mutations in lamin A/C in patients with Emery-Dreifuss
RT   muscular dystrophy.";
RL   Am. J. Med. Genet. 102:359-367(2001).
RN   [64]
RP   VARIANT CMD1A LYS-203.
RX   PubMed=11561226; DOI=10.1054/jcaf.2001.26339;
RA   Jakobs P.M., Hanson E.L., Crispell K.A., Toy W., Keegan H., Schilling K.,
RA   Icenogle T.B., Litt M., Hershberger R.E.;
RT   "Novel lamin A/C mutations in two families with dilated cardiomyopathy and
RT   conduction system disease.";
RL   J. Card. Fail. 7:249-256(2001).
RN   [65]
RP   CHARACTERIZATION OF VARIANTS CMD1A GLY-60; ARG-85; LYS-195 AND GLY-203,
RP   CHARACTERIZATION OF VARIANTS EDMD2 LYS-358; LYS-371; LYS-386; TRP-453;
RP   SER-520; PRO-527; LYS-528 AND PRO-530, AND CHARACTERIZATION OF VARIANTS
RP   FPLD2 GLN-482; TRP-482 AND ASN-486.
RX   PubMed=11792809; DOI=10.1242/jcs.114.24.4435;
RA   Oestlund C., Bonne G., Schwartz K., Worman H.J.;
RT   "Properties of lamin A mutants found in Emery-Dreifuss muscular dystrophy,
RT   cardiomyopathy and Dunnigan-type partial lipodystrophy.";
RL   J. Cell Sci. 114:4435-4445(2001).
RN   [66]
RP   VARIANT EDMD2 HIS-481.
RX   PubMed=11525883; DOI=10.1016/s0960-8966(01)00207-3;
RA   Kitaguchi T., Matsubara S., Sato M., Miyamoto K., Hirai S., Schwartz K.,
RA   Bonne G.;
RT   "A missense mutation in the exon 8 of lamin A/C gene in a Japanese case of
RT   autosomal dominant limb-girdle muscular dystrophy and cardiac conduction
RT   block.";
RL   Neuromuscul. Disord. 11:542-546(2001).
RN   [67]
RP   VARIANT CMD1A PRO-215.
RX   PubMed=12486434; DOI=10.1067/mhj.2002.126737;
RA   Hershberger R.E., Hanson E.L., Jakobs P.M., Keegan H., Coates K.,
RA   Bousman S., Litt M.;
RT   "A novel lamin A/C mutation in a family with dilated cardiomyopathy,
RT   prominent conduction system disease, and need for permanent pacemaker
RT   implantation.";
RL   Am. Heart J. 144:1081-1086(2002).
RN   [68]
RP   VARIANT CMT2B1 CYS-298, AND FUNCTION.
RX   PubMed=11799477; DOI=10.1086/339274;
RA   De Sandre-Giovannoli A., Chaouch M., Kozlov S., Vallat J.-M., Tazir M.,
RA   Kassouri N., Szepetowski P., Hammadouche T., Vandenberghe A., Stewart C.L.,
RA   Grid D., Levy N.;
RT   "Homozygous defects in LMNA, encoding lamin A/C nuclear-envelope proteins,
RT   cause autosomal recessive axonal neuropathy in human (Charcot-Marie-Tooth
RT   disorder type 2) and mouse.";
RL   Am. J. Hum. Genet. 70:726-736(2002).
RN   [69]
RP   ERRATUM OF PUBMED:11799477.
RA   De Sandre-Giovannoli A., Chaouch M., Kozlov S., Vallat J.-M., Tazir M.,
RA   Kassouri N., Szepetowski P., Hammadouche T., Vandenberghe A., Stewart C.L.,
RA   Grid D., Levy N.;
RL   Am. J. Hum. Genet. 70:1075-1075(2002).
RN   [70]
RP   VARIANT MADA HIS-527, AND FUNCTION.
RX   PubMed=12075506; DOI=10.1086/341908;
RA   Novelli G., Muchir A., Sangiuolo F., Helbling-Leclerc A., D'Apice M.R.,
RA   Massart C., Capon F., Sbraccia P., Federici M., Lauro R., Tudisco C.,
RA   Pallotta R., Scarano G., Dallapiccola B., Merlini L., Bonne G.;
RT   "Mandibuloacral dysplasia is caused by a mutation in LMNA-encoding lamin
RT   A/C.";
RL   Am. J. Hum. Genet. 71:426-431(2002).
RN   [71]
RP   VARIANTS FPLD2 TRP-28 AND GLY-62.
RX   PubMed=12015247; DOI=10.1016/s0002-9343(02)01070-7;
RA   Garg A., Speckman R.A., Bowcock A.M.;
RT   "Multisystem dystrophy syndrome due to novel missense mutations in the
RT   amino-terminal head and alpha-helical rod domains of the lamin A/C gene.";
RL   Am. J. Med. 112:549-555(2002).
RN   [72]
RP   VARIANTS CMD1A GLU-97; TRP-190 AND LYS-317.
RX   PubMed=11897440; DOI=10.1016/s0735-1097(02)01724-2;
RA   Arbustini E., Pilotto A., Repetto A., Grasso M., Negri A., Diegoli M.,
RA   Campana C., Scelsi L., Baldini E., Gavazzi A., Tavazzi L.;
RT   "Autosomal dominant dilated cardiomyopathy with atrioventricular block: a
RT   lamin A/C defect-related disease.";
RL   J. Am. Coll. Cardiol. 39:981-990(2002).
RN   [73]
RP   VARIANT EDMD2 GLN-249, AND VARIANT EDMD2 LEU-377.
RX   PubMed=12032588; DOI=10.1007/s100380200029;
RA   Ki C.-S., Hong J.S., Jeong G.-Y., Ahn K.J., Choi K.-M., Kim D.-K.,
RA   Kim J.-W.;
RT   "Identification of lamin A/C (LMNA) gene mutations in Korean patients with
RT   autosomal dominant Emery-Dreifuss muscular dystrophy and limb-girdle
RT   muscular dystrophy 1B.";
RL   J. Hum. Genet. 47:225-228(2002).
RN   [74]
RP   VARIANTS FPLD2 GLY-60 AND PRO-527.
RX   PubMed=12196663; DOI=10.1212/wnl.59.4.620;
RA   van der Kooi A.J., Bonne G., Eymard B., Duboc D., Talim B.,
RA   Van der Valk M., Reiss P., Richard P., Demay L., Merlini L., Schwartz K.,
RA   Busch H.F.M., de Visser M.;
RT   "Lamin A/C mutations with lipodystrophy, cardiac abnormalities, and
RT   muscular dystrophy.";
RL   Neurology 59:620-623(2002).
RN   [75]
RP   VARIANTS EDMD2 LYS-32 DEL; ASN-63; GLN-336; GLN-343 AND CYS-401.
RX   PubMed=12467752; DOI=10.1016/s0960-8966(02)00178-5;
RA   Vytopil M., Ricci E., Dello Russo A., Hanisch F., Neudecker S., Zierz S.,
RA   Ricotti R., Demay L., Richard P., Wehnert M., Bonne G., Merlini L.,
RA   Toniolo D.;
RT   "Frequent low penetrance mutations in the Lamin A/C gene, causing Emery
RT   Dreifuss muscular dystrophy.";
RL   Neuromuscul. Disord. 12:958-963(2002).
RN   [76]
RP   VARIANT CMD1A CYS-541.
RX   PubMed=14675861; DOI=10.1016/s1388-9842(03)00149-1;
RA   Forissier J.-F., Bonne G., Bouchier C., Duboscq-Bidot L., Richard P.,
RA   Wisnewski C., Briault S., Moraine C., Dubourg O., Schwartz K., Komajda M.;
RT   "Apical left ventricular aneurysm without atrio-ventricular block due to a
RT   lamin A/C gene mutation.";
RL   Eur. J. Heart Fail. 5:821-825(2003).
RN   [77]
RP   VARIANT EDMD2 HIS-377.
RX   PubMed=12673789; DOI=10.1002/humu.10170;
RA   Charniot J.-C., Pascal C., Bouchier C., Sebillon P., Salama J.,
RA   Duboscq-Bidot L., Peuchmaurd M., Desnos M., Artigou J.-Y., Komajda M.;
RT   "Functional consequences of an LMNA mutation associated with a new cardiac
RT   and non-cardiac phenotype.";
RL   Hum. Mutat. 21:473-481(2003).
RN   [78]
RP   VARIANTS CMD1A LEU-89; HIS-377 AND LEU-573.
RX   PubMed=12628721; DOI=10.1016/s0735-1097(02)02954-6;
RG   Familial dilated cardiomyopathy registry research group;
RA   Taylor M.R.G., Fain P.R., Sinagra G., Robinson M.L., Robertson A.D.,
RA   Carniel E., Di Lenarda A., Bohlmeyer T.J., Ferguson D.A., Brodsky G.L.,
RA   Boucek M.M., Lascor J., Moss A.C., Li W.-L.P., Stetler G.L., Muntoni F.,
RA   Bristow M.R., Mestroni L.;
RT   "Natural history of dilated cardiomyopathy due to lamin A/C gene
RT   mutations.";
RL   J. Am. Coll. Cardiol. 41:771-780(2003).
RN   [79]
RP   ERRATUM OF PUBMED:12628721.
RG   Familial dilated cardiomyopathy registry research group;
RA   Taylor M.R.G., Fain P.R., Sinagra G., Robinson M.L., Robertson A.D.,
RA   Carniel E., Di Lenarda A., Bohlmeyer T.J., Ferguson D.A., Brodsky G.L.,
RA   Boucek M.M., Lascor J., Moss A.C., Li W.-L.P., Stetler G.L., Muntoni F.,
RA   Bristow M.R., Mestroni L.;
RL   J. Am. Coll. Cardiol. 42:590-590(2003).
RN   [80]
RP   VARIANT FPLD2 LEU-133.
RX   PubMed=12629077; DOI=10.1210/jc.2002-021506;
RA   Caux F., Dubosclard E., Lascols O., Buendia B., Chazouilleres O., Cohen A.,
RA   Courvalin J.-C., Laroche L., Capeau J., Vigouroux C., Christin-Maitre S.;
RT   "A new clinical condition linked to a novel mutation in lamins A and C with
RT   generalized lipoatrophy, insulin-resistant diabetes, disseminated
RT   leukomelanodermic papules, liver steatosis, and cardiomyopathy.";
RL   J. Clin. Endocrinol. Metab. 88:1006-1013(2003).
RN   [81]
RP   VARIANTS HGPS CYS-471; CYS-527 AND SER-608.
RX   PubMed=12768443; DOI=10.1007/s10038-003-0025-3;
RA   Cao H., Hegele R.A.;
RT   "LMNA is mutated in Hutchinson-Gilford progeria (MIM 176670) but not in
RT   Wiedemann-Rautenstrauch progeroid syndrome (MIM 264090).";
RL   J. Hum. Genet. 48:271-274(2003).
RN   [82]
RP   VARIANT CMD1A LYS-161.
RX   PubMed=12920062; DOI=10.1136/jmg.40.8.560;
RA   Sebillon P., Bouchier C., Bidot L.D., Bonne G., Ahamed K., Charron P.,
RA   Drouin-Garraud V., Millaire A., Desrumeaux G., Benaiche A., Charniot J.-C.,
RA   Schwartz K., Villard E., Komajda M.;
RT   "Expanding the phenotype of LMNA mutations in dilated cardiomyopathy and
RT   functional consequences of these mutations.";
RL   J. Med. Genet. 40:560-567(2003).
RN   [83]
RP   VARIANTS EDMD2 GLY-25; LYS-32 DEL; VAL-35; GLY-65; GLU-112 DEL; PRO-248;
RP   GLN-249; CYS-267; VAL-446; TRP-453; ARG-528 AND HIS-541, AND VARIANT CMD1A
RP   CYS-435.
RX   PubMed=14684700; DOI=10.1136/jmg.40.12.e132;
RA   Vytopil M., Benedetti S., Ricci E., Galluzzi G., Dello Russo A.,
RA   Merlini L., Boriani G., Gallina M., Morandi L., Politano L., Moggio M.,
RA   Chiveri L., Hausmanova-Petrusewicz I., Ricotti R., Vohanka S., Toman J.,
RA   Toniolo D.;
RT   "Mutation analysis of the lamin A/C gene (LMNA) among patients with
RT   different cardiomuscular phenotypes.";
RL   J. Med. Genet. 40:E132-E132(2003).
RN   [84]
RP   VARIANT CMDHH PRO-57, VARIANT HGPS ARG-140, AND FUNCTION.
RX   PubMed=12927431; DOI=10.1016/s0140-6736(03)14069-x;
RA   Chen L., Lee L., Kudlow B.A., Dos Santos H.G., Sletvold O., Shafeghati Y.,
RA   Botha E.G., Garg A., Hanson N.B., Martin G.M., Mian I.S., Kennedy B.K.,
RA   Oshima J.;
RT   "LMNA mutations in atypical Werner's syndrome.";
RL   Lancet 362:440-445(2003).
RN   [85]
RP   VARIANTS EDMD2 ASN-63; PRO-140; GLN-249; LEU-377; LYS-386 AND PRO-527.
RX   PubMed=12649505; DOI=10.1161/01.str.0000064322.47667.49;
RA   Boriani G., Gallina M., Merlini L., Bonne G., Toniolo D., Amati S.,
RA   Biffi M., Martignani C., Frabetti L., Bonvicini M., Rapezzi C., Branzi A.;
RT   "Clinical relevance of atrial fibrillation/flutter, stroke, pacemaker
RT   implant, and heart failure in Emery-Dreifuss muscular dystrophy: a long-
RT   term longitudinal study.";
RL   Stroke 34:901-908(2003).
RN   [86]
RP   VARIANTS CMD1A TRP-190 AND LEU-349.
RX   PubMed=15219508; DOI=10.1016/j.amjcard.2004.03.029;
RA   Hermida-Prieto M., Monserrat L., Castro-Beiras A., Laredo R., Soler R.,
RA   Peteiro J., Rodriguez E., Bouzas B., Alvarez N., Muniz J., Crespo-Leiro M.;
RT   "Familial dilated cardiomyopathy and isolated left ventricular
RT   noncompaction associated with lamin A/C gene mutations.";
RL   Am. J. Cardiol. 94:50-54(2004).
RN   [87]
RP   VARIANT CMD1A PRO-143.
RX   PubMed=15140538; DOI=10.1016/j.ehj.2004.01.020;
RA   Kaerkkaeinen S., Helioe T., Miettinen R., Tuomainen P., Peltola P.,
RA   Rummukainen J., Ylitalo K., Kaartinen M., Kuusisto J., Toivonen L.,
RA   Nieminen M.S., Laakso M., Peuhkurinen K.;
RT   "A novel mutation, Ser143Pro, in the lamin A/C gene is common in Finnish
RT   patients with familial dilated cardiomyopathy.";
RL   Eur. Heart J. 25:885-893(2004).
RN   [88]
RP   INVOLVEMENT IN RSDM2, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=15317753; DOI=10.1093/hmg/ddh265;
RA   Navarro C.L., De Sandre-Giovannoli A., Bernard R., Boccaccio I., Boyer A.,
RA   Genevieve D., Hadj-Rabia S., Gaudy-Marqueste C., Smitt H.S., Vabres P.,
RA   Faivre L., Verloes A., Van Essen T., Flori E., Hennekam R., Beemer F.A.,
RA   Laurent N., Le Merrer M., Cau P., Levy N.;
RT   "Lamin A and ZMPSTE24 (FACE-1) defects cause nuclear disorganization and
RT   identify restrictive dermopathy as a lethal neonatal laminopathy.";
RL   Hum. Mol. Genet. 13:2493-2503(2004).
RN   [89]
RP   VARIANT HGPS CYS-644, AND VARIANTS ILE-10 AND VAL-578.
RX   PubMed=15060110; DOI=10.1136/jmg.2003.015651;
RA   Csoka A.B., Cao H., Sammak P.J., Constantinescu D., Schatten G.P.,
RA   Hegele R.A.;
RT   "Novel lamin A/C gene (LMNA) mutations in atypical progeroid syndromes.";
RL   J. Med. Genet. 41:304-308(2004).
RN   [90]
RP   VARIANT HGPS ASN-542.
RX   PubMed=15286156; DOI=10.1136/jmg.2004.019661;
RA   Plasilova M., Chattopadhyay C., Pal P., Schaub N.A., Buechner S.A.,
RA   Mueller H., Miny P., Ghosh A., Heinimann K.;
RT   "Homozygous missense mutation in the lamin A/C gene causes autosomal
RT   recessive Hutchinson-Gilford progeria syndrome.";
RL   J. Med. Genet. 41:609-614(2004).
RN   [91]
RP   VARIANT CMT2 ASP-33, AND VARIANT EDMD2 GLY-33.
RX   PubMed=14985400; DOI=10.1136/jmg.2003.013383;
RA   Goizet C., Yaou R.B., Demay L., Richard P., Bouillot S., Rouanet M.,
RA   Hermosilla E., Le Masson G., Lagueny A., Bonne G., Ferrer X.;
RT   "A new mutation of the lamin A/C gene leading to autosomal dominant axonal
RT   neuropathy, muscular dystrophy, cardiac disease, and leuconychia.";
RL   J. Med. Genet. 41:E29-E29(2004).
RN   [92]
RP   SUBCELLULAR LOCATION, CHARACTERIZATION OF VARIANTS EDMD2 LYS-32 DEL;
RP   SER-63; GLN-249; LYS-358; CYS-401; TRP-453 AND PRO-527, CHARACTERIZATION OF
RP   VARIANTS EDMD2 LYS-208 DEL AND HIS-377, CHARACTERIZATION OF VARIANT FPLD2
RP   LEU-482, AND CHARACTERIZATION OF VARIANT CMD1A CYS-541.
RX   PubMed=15372542; DOI=10.1002/mus.20122;
RA   Muchir A., Medioni J., Laluc M., Massart C., Arimura T., van der Kooi A.J.,
RA   Desguerre I., Mayer M., Ferrer X., Briault S., Hirano M., Worman H.J.,
RA   Mallet A., Wehnert M., Schwartz K., Bonne G.;
RT   "Nuclear envelope alterations in fibroblasts from patients with muscular
RT   dystrophy, cardiomyopathy, and partial lipodystrophy carrying lamin A/C
RT   gene mutations.";
RL   Muscle Nerve 30:444-450(2004).
RN   [93]
RP   VARIANT HGPS PHE-143.
RX   PubMed=15622532; DOI=10.1002/ana.20359;
RA   Kirschner J., Brune T., Wehnert M., Denecke J., Wasner C., Feuer A.,
RA   Marquardt T., Ketelsen U.-P., Wieacker P., Boennemann C.G.,
RA   Korinthenberg R.;
RT   "p.S143F mutation in lamin A/C: a new phenotype combining myopathy and
RT   progeria.";
RL   Ann. Neurol. 57:148-151(2005).
RN   [94]
RP   VARIANT CMDA1 ASN-260.
RX   PubMed=16156025;
RA   Arbustini Eloisa A.E., Pilotto A., Pasotti M., Grasso M., Diegoli M.,
RA   Campana C., Gavazzi A., Alessandra R., Tavazzi L.;
RT   "Gene symbol: LMNA. Disease: cardiomyopathy, dilated, with conduction
RT   defect 1.";
RL   Hum. Genet. 117:298-298(2005).
RN   [95]
RP   VARIANT MADA VAL-529.
RX   PubMed=15998779; DOI=10.1210/jc.2004-2560;
RA   Garg A., Cogulu O., Ozkinay F., Onay H., Agarwal A.K.;
RT   "A novel homozygous Ala529Val LMNA mutation in Turkish patients with
RT   mandibuloacral dysplasia.";
RL   J. Clin. Endocrinol. Metab. 90:5259-5264(2005).
RN   [96]
RP   VARIANT EDMD2 HIS-377, AND VARIANTS EDMD2 ASN-63; PRO-140; GLN-190; GLN-249
RP   AND PRO-527.
RX   PubMed=15744034; DOI=10.1136/jmg.2004.026112;
RA   Cenni V., Sabatelli P., Mattioli E., Marmiroli S., Capanni C., Ognibene A.,
RA   Squarzoni S., Maraldi N.M., Bonne G., Columbaro M., Merlini L.,
RA   Lattanzi G.;
RT   "Lamin A N-terminal phosphorylation is associated with myoblast activation:
RT   impairment in Emery-Dreifuss muscular dystrophy.";
RL   J. Med. Genet. 42:214-220(2005).
RN   [97]
RP   VARIANT MADA LEU-573.
RX   PubMed=16278265; DOI=10.1210/jc.2005-1297;
RA   Van Esch H., Agarwal A.K., Debeer P., Fryns J.-P., Garg A.;
RT   "A homozygous mutation in the lamin A/C gene associated with a novel
RT   syndrome of arthropathy, tendinous calcinosis, and progeroid features.";
RL   J. Clin. Endocrinol. Metab. 91:517-521(2006).
RN   [98]
RP   VARIANT CMDHH ARG-59.
RX   PubMed=17150192; DOI=10.1016/j.bbrc.2006.11.070;
RA   Nguyen D., Leistritz D.F., Turner L., MacGregor D., Ohson K., Dancey P.,
RA   Martin G.M., Oshima J.;
RT   "Collagen expression in fibroblasts with a novel LMNA mutation.";
RL   Biochem. Biophys. Res. Commun. 352:603-608(2007).
RN   [99]
RP   VARIANTS FPLD2 ASN-230; CYS-399 AND LEU-573.
RX   PubMed=17250669; DOI=10.1111/j.1399-0004.2007.00740.x;
RA   Lanktree M., Cao H., Rabkin S.W., Hanna A., Hegele R.A.;
RT   "Novel LMNA mutations seen in patients with familial partial lipodystrophy
RT   subtype 2 (FPLD2; MIM 151660).";
RL   Clin. Genet. 71:183-186(2007).
RN   [100]
RP   VARIANT EDMD2 HIS-377.
RX   PubMed=17136397; DOI=10.1007/s10048-006-0070-0;
RA   Rudnik-Schoeneborn S., Botzenhart E., Eggermann T., Senderek J.,
RA   Schoser B.G.H., Schroeder R., Wehnert M., Wirth B., Zerres K.;
RT   "Mutations of the LMNA gene can mimic autosomal dominant proximal spinal
RT   muscular atrophy.";
RL   Neurogenetics 8:137-142(2007).
RN   [101]
RP   VARIANT PRO-421.
RX   PubMed=17711925; DOI=10.1210/jc.2007-0654;
RA   Decaudain A., Vantyghem M.C., Guerci B., Hecart A.C., Auclair M.,
RA   Reznik Y., Narbonne H., Ducluzeau P.H., Donadille B., Lebbe C.,
RA   Bereziat V., Capeau J., Lascols O., Vigouroux C.;
RT   "New metabolic phenotypes in laminopathies: LMNA mutations in patients with
RT   severe metabolic syndrome.";
RL   J. Clin. Endocrinol. Metab. 92:4835-4844(2007).
RN   [102]
RP   VARIANTS MDCL SER-39; PRO-50; TRP-249; PRO-302; LYS-358; SER-380; PRO-453;
RP   PRO-455 AND ASP-456.
RX   PubMed=18551513; DOI=10.1002/ana.21417;
RA   Quijano-Roy S., Mbieleu B., Bonnemann C.G., Jeannet P.Y., Colomer J.,
RA   Clarke N.F., Cuisset J.M., Roper H., De Meirleir L., D'Amico A.,
RA   Ben Yaou R., Nascimento A., Barois A., Demay L., Bertini E., Ferreiro A.,
RA   Sewry C.A., Romero N.B., Ryan M., Muntoni F., Guicheney P., Richard P.,
RA   Bonne G., Estournet B.;
RT   "De novo LMNA mutations cause a new form of congenital muscular
RT   dystrophy.";
RL   Ann. Neurol. 64:177-186(2008).
RN   [103]
RP   INVOLVEMENT IN HHS-SLOVENIAN, AND FUNCTION.
RX   PubMed=18611980; DOI=10.1136/jmg.2008.060020;
RA   Renou L., Stora S., Yaou R.B., Volk M., Sinkovec M., Demay L., Richard P.,
RA   Peterlin B., Bonne G.;
RT   "Heart-hand syndrome of Slovenian type: a new kind of laminopathy.";
RL   J. Med. Genet. 45:666-671(2008).
RN   [104]
RP   FUNCTION, INTERACTION WITH IFFO1, SUBCELLULAR LOCATION, MUTAGENESIS OF
RP   SER-22; GLU-358 AND ARG-386, AND REGION.
RX   PubMed=31548606; DOI=10.1038/s41556-019-0388-0;
RA   Li W., Bai X., Li J., Zhao Y., Liu J., Zhao H., Liu L., Ding M., Wang Q.,
RA   Shi F.Y., Hou M., Ji J., Gao G., Guo R., Sun Y., Liu Y., Xu D.;
RT   "The nucleoskeleton protein IFFO1 immobilizes broken DNA and suppresses
RT   chromosome translocation during tumorigenesis.";
RL   Nat. Cell Biol. 21:1273-1285(2019).
RN   [105]
RP   VARIANT CMDHH ARG-59.
RX   PubMed=19283854; DOI=10.1002/ajmg.a.32627;
RA   McPherson E., Turner L., Zador I., Reynolds K., Macgregor D.,
RA   Giampietro P.F.;
RT   "Ovarian failure and dilated cardiomyopathy due to a novel lamin
RT   mutation.";
RL   Am. J. Med. Genet. A 149:567-572(2009).
RN   [106]
RP   VARIANTS SER-125; ILE-415 AND PRO-488.
RX   PubMed=19427440; DOI=10.1016/j.amjcard.2009.01.354;
RA   Brauch K.M., Chen L.Y., Olson T.M.;
RT   "Comprehensive mutation scanning of LMNA in 268 patients with lone atrial
RT   fibrillation.";
RL   Am. J. Cardiol. 103:1426-1428(2009).
RN   [107]
RP   VARIANT CMD1A CYS-541.
RX   PubMed=19167105; DOI=10.1016/j.ijcard.2008.12.083;
RA   Saj M., Jankowska A., Lewandowski M., Szwed H., Szperl M., Ploski R.,
RA   Bilinska Z.T.;
RT   "Dilated cardiomyopathy with profound segmental wall motion abnormalities
RT   and ventricular arrhythmia caused by the R541C mutation in the LMNA gene.";
RL   Int. J. Cardiol. 144:E51-E53(2010).
RN   [108]
RP   VARIANTS CMD1A PHE-92; LYS-161; LYS-317 AND ARG-523.
RX   PubMed=21846512; DOI=10.1016/j.ejmg.2011.07.005;
RA   Millat G., Bouvagnet P., Chevalier P., Sebbag L., Dulac A., Dauphin C.,
RA   Jouk P.S., Delrue M.A., Thambo J.B., Le Metayer P., Seronde M.F.,
RA   Faivre L., Eicher J.C., Rousson R.;
RT   "Clinical and mutational spectrum in a cohort of 105 unrelated patients
RT   with dilated cardiomyopathy.";
RL   Eur. J. Med. Genet. 54:E570-E575(2011).
RN   [109]
RP   VARIANT HGPS LYS-138.
RX   PubMed=21791255; DOI=10.1016/j.ejmg.2011.06.012;
RA   Gonzalez-Quereda L., Delgadillo V., Juan-Mateu J., Verdura E.,
RA   Rodriguez M.J., Baiget M., Pineda M., Gallano P.;
RT   "LMNA mutation in progeroid syndrome in association with strokes.";
RL   Eur. J. Med. Genet. 54:E576-E579(2011).
RN   [110]
RP   VARIANTS EDMD2 SER-39; CYS-45; PRO-150; PRO-189; ARG-190 INS; LEU-206;
RP   TRP-249; GLN-249; PRO-268; PRO-271; PRO-294; PRO-295; PRO-303; GLN-355 DEL;
RP   LYS-358; LYS-361; LYS-386; ASP-449; TRP-453; PRO-454; TYR-461; ARG-467;
RP   PRO-527; LYS-528; ARG-528; SER-541; PRO-541; SER-602 AND CYS-644, AND
RP   CHARACTERIZATION OF VARIANTS EDMD2 PRO-25; TRP-249; ILE-456 AND PRO-541.
RX   PubMed=20848652; DOI=10.1002/humu.21361;
RA   Scharner J., Brown C.A., Bower M., Iannaccone S.T., Khatri I.A.,
RA   Escolar D., Gordon E., Felice K., Crowe C.A., Grosmann C., Meriggioli M.N.,
RA   Asamoah A., Gordon O., Gnocchi V.F., Ellis J.A., Mendell J.R., Zammit P.S.;
RT   "Novel LMNA mutations in patients with Emery-Dreifuss muscular dystrophy
RT   and functional characterization of four LMNA mutations.";
RL   Hum. Mutat. 32:152-167(2011).
RN   [111]
RP   VARIANTS ASP-411 AND ASP-631.
RX   PubMed=21724554; DOI=10.1093/hmg/ddr294;
RA   Dutour A., Roll P., Gaborit B., Courrier S., Alessi M.C., Tregouet D.A.,
RA   Angelis F., Robaglia-Schlupp A., Lesavre N., Cau P., Levy N., Badens C.,
RA   Morange P.E.;
RT   "High prevalence of laminopathies among patients with metabolic syndrome.";
RL   Hum. Mol. Genet. 20:3779-3786(2011).
RN   [112]
RP   VARIANT EDMD3 GLN-225, AND FUNCTION.
RX   PubMed=22431096; DOI=10.1002/mus.22324;
RA   Jimenez-Escrig A., Gobernado I., Garcia-Villanueva M., Sanchez-Herranz A.;
RT   "Autosomal recessive Emery-Dreifuss muscular dystrophy caused by a novel
RT   mutation (R225Q) in the lamin A/C gene identified by exome sequencing.";
RL   Muscle Nerve 45:605-610(2012).
RN   [113]
RP   CHARACTERIZATION OF VARIANTS CYS-401; ASP-411; CYS-413; ILE-415; CYS-419;
RP   PRO-421 AND GLY-427, AND INTERACTION WITH SYNE2.
RX   PubMed=23977161; DOI=10.1371/journal.pone.0071850;
RA   Yang L., Munck M., Swamvdinathan K., Kapinos L.E., Noegel A.A., Neumann S.;
RT   "Mutations in LMNA modulate the lamin A--Nesprin-2 interaction and cause
RT   LINC complex alterations.";
RL   PLoS ONE 8:E71850-E71850(2013).
RN   [114]
RP   VARIANT FPLD2 GLU-515.
RX   PubMed=24485160; DOI=10.1016/j.diabet.2013.12.008;
RA   Chirico V., Ferrau V., Loddo I., Briuglia S., Amorini M., Salpietro V.,
RA   Lacquaniti A., Salpietro C., Arrigo T.;
RT   "LMNA gene mutation as a model of cardiometabolic dysfunction: from genetic
RT   analysis to treatment response.";
RL   Diabetes Metab. 40:224-228(2014).
RN   [115]
RP   VARIANT EDMD3 SER-24, AND VARIANT EDMD2 CYS-259.
RX   PubMed=27234031; DOI=10.1111/cge.12810;
RA   Fattahi Z., Kalhor Z., Fadaee M., Vazehan R., Parsimehr E., Abolhassani A.,
RA   Beheshtian M., Zamani G., Nafissi S., Nilipour Y., Akbari M.R., Kahrizi K.,
RA   Kariminejad A., Najmabadi H.;
RT   "Improved diagnostic yield of neuromuscular disorders applying clinical
RT   exome sequencing in patients arising from a consanguineous population.";
RL   Clin. Genet. 91:386-402(2017).
CC   -!- FUNCTION: Lamins are components of the nuclear lamina, a fibrous layer
CC       on the nucleoplasmic side of the inner nuclear membrane, which is
CC       thought to provide a framework for the nuclear envelope and may also
CC       interact with chromatin (PubMed:10080180, PubMed:10580070,
CC       PubMed:10587585, PubMed:10814726, PubMed:11799477, PubMed:12075506,
CC       PubMed:12927431, PubMed:15317753, PubMed:18551513, PubMed:18611980,
CC       PubMed:22431096, PubMed:23666920, PubMed:31548606). Lamin A and C are
CC       present in equal amounts in the lamina of mammals (PubMed:10080180,
CC       PubMed:10580070, PubMed:10587585, PubMed:10814726, PubMed:11799477,
CC       PubMed:12075506, PubMed:12927431, PubMed:15317753, PubMed:18551513,
CC       PubMed:18611980, PubMed:22431096, PubMed:23666920, PubMed:31548606).
CC       Recruited by DNA repair proteins XRCC4 and IFFO1 to the DNA double-
CC       strand breaks (DSBs) to prevent chromosome translocation by
CC       immobilizing broken DNA ends (PubMed:31548606). Plays an important role
CC       in nuclear assembly, chromatin organization, nuclear membrane and
CC       telomere dynamics. Required for normal development of peripheral
CC       nervous system and skeletal muscle and for muscle satellite cell
CC       proliferation (PubMed:10080180, PubMed:10814726, PubMed:11799477,
CC       PubMed:18551513, PubMed:22431096). Required for osteoblastogenesis and
CC       bone formation (PubMed:12075506, PubMed:15317753, PubMed:18611980).
CC       Also prevents fat infiltration of muscle and bone marrow, helping to
CC       maintain the volume and strength of skeletal muscle and bone
CC       (PubMed:10587585). Required for cardiac homeostasis (PubMed:10580070,
CC       PubMed:12927431, PubMed:23666920, PubMed:18611980).
CC       {ECO:0000269|PubMed:10080180, ECO:0000269|PubMed:10580070,
CC       ECO:0000269|PubMed:10587585, ECO:0000269|PubMed:10814726,
CC       ECO:0000269|PubMed:11799477, ECO:0000269|PubMed:12075506,
CC       ECO:0000269|PubMed:12927431, ECO:0000269|PubMed:15317753,
CC       ECO:0000269|PubMed:18551513, ECO:0000269|PubMed:18611980,
CC       ECO:0000269|PubMed:22431096, ECO:0000269|PubMed:23666920,
CC       ECO:0000269|PubMed:31548606}.
CC   -!- FUNCTION: Prelamin-A/C can accelerate smooth muscle cell senescence. It
CC       acts to disrupt mitosis and induce DNA damage in vascular smooth muscle
CC       cells (VSMCs), leading to mitotic failure, genomic instability, and
CC       premature senescence. {ECO:0000269|PubMed:20458013}.
CC   -!- SUBUNIT: Homodimer of lamin A and lamin C (PubMed:15476822). Interacts
CC       with lamin-associated polypeptides IA, IB and TMPO-alpha, RB1 and with
CC       emerin (PubMed:12475961). Interacts with SREBF1, SREBF2, SUN2 and
CC       TMEM43 (By similarity). Interacts with TMEM201 (By similarity).
CC       Proteolytically processed isoform A interacts with NARF
CC       (PubMed:10514485). Interacts with SUN1 (PubMed:19933576). Interacts
CC       with MLIP (PubMed:21498514). Interacts with DMPK; may regulate nuclear
CC       envelope stability (PubMed:21949239). Interacts with SUV39H1; the
CC       interaction increases stability of SUV39H1 (PubMed:23695662). Interacts
CC       with SYNE2 (PubMed:23977161). Interacts with ITSN1 isoform 2
CC       (PubMed:29599122). Interacts with IFFO1; enables the formation of an
CC       interior nucleoskeleton that is recruited to DNA double-strand breaks
CC       (PubMed:31548606). {ECO:0000250|UniProtKB:P48678,
CC       ECO:0000269|PubMed:10514485, ECO:0000269|PubMed:12475961,
CC       ECO:0000269|PubMed:15476822, ECO:0000269|PubMed:19933576,
CC       ECO:0000269|PubMed:21498514, ECO:0000269|PubMed:21949239,
CC       ECO:0000269|PubMed:23695662, ECO:0000269|PubMed:23977161,
CC       ECO:0000269|PubMed:29599122, ECO:0000269|PubMed:31548606}.
CC   -!- SUBUNIT: [Prelamin-A/C]: Interacts with EMD.
CC       {ECO:0000269|PubMed:19323649}.
CC   -!- SUBUNIT: [Isoform C]: Interacts (via C-terminus) with LEMD2 (via N-
CC       terminus) (in vitro). {ECO:0000269|PubMed:16339967}.
CC   -!- INTERACTION:
CC       P02545; Q6H8Q1-8: ABLIM2; NbExp=3; IntAct=EBI-351935, EBI-16436655;
CC       P02545; P18054: ALOX12; NbExp=4; IntAct=EBI-351935, EBI-1633210;
CC       P02545; Q96DX5: ASB9; NbExp=3; IntAct=EBI-351935, EBI-745641;
CC       P02545; Q8WXF7: ATL1; NbExp=3; IntAct=EBI-351935, EBI-2410266;
CC       P02545; P46379-2: BAG6; NbExp=3; IntAct=EBI-351935, EBI-10988864;
CC       P02545; Q8TBE0: BAHD1; NbExp=3; IntAct=EBI-351935, EBI-742750;
CC       P02545; Q9ULD4-2: BRPF3; NbExp=3; IntAct=EBI-351935, EBI-23662416;
CC       P02545; Q96GN5-2: CDCA7L; NbExp=3; IntAct=EBI-351935, EBI-9091443;
CC       P02545; Q9UII6: DUSP13; NbExp=7; IntAct=EBI-351935, EBI-749800;
CC       P02545; P50402: EMD; NbExp=7; IntAct=EBI-351935, EBI-489887;
CC       P02545; Q3B820: FAM161A; NbExp=3; IntAct=EBI-351935, EBI-719941;
CC       P02545; A6H8Z2-3: FAM221B; NbExp=3; IntAct=EBI-351935, EBI-25843965;
CC       P02545; P58499: FAM3B; NbExp=3; IntAct=EBI-351935, EBI-12955347;
CC       P02545; Q8IZU1: FAM9A; NbExp=3; IntAct=EBI-351935, EBI-8468186;
CC       P02545; Q8NEA9: GMCL2; NbExp=3; IntAct=EBI-351935, EBI-745707;
CC       P02545; P16104: H2AX; NbExp=3; IntAct=EBI-351935, EBI-494830;
CC       P02545; Q71DI3: H3C15; NbExp=6; IntAct=EBI-351935, EBI-750650;
CC       P02545; Q0D2I5-5: IFFO1; NbExp=4; IntAct=EBI-351935, EBI-21251044;
CC       P02545; Q13123: IK; NbExp=3; IntAct=EBI-351935, EBI-713456;
CC       P02545; Q14005-2: IL16; NbExp=3; IntAct=EBI-351935, EBI-17178971;
CC       P02545; Q96EL1: INKA1; NbExp=3; IntAct=EBI-351935, EBI-10285157;
CC       P02545; Q8NA54: IQUB; NbExp=3; IntAct=EBI-351935, EBI-10220600;
CC       P02545; Q99612: KLF6; NbExp=3; IntAct=EBI-351935, EBI-714994;
CC       P02545; P60409: KRTAP10-7; NbExp=3; IntAct=EBI-351935, EBI-10172290;
CC       P02545; P20700: LMNB1; NbExp=10; IntAct=EBI-351935, EBI-968218;
CC       P02545; Q03252: LMNB2; NbExp=6; IntAct=EBI-351935, EBI-2830427;
CC       P02545; O76041: NEBL; NbExp=3; IntAct=EBI-351935, EBI-2880203;
CC       P02545; Q12986: NFX1; NbExp=3; IntAct=EBI-351935, EBI-2130062;
CC       P02545; Q9Y239: NOD1; NbExp=3; IntAct=EBI-351935, EBI-1051262;
CC       P02545; Q13133-3: NR1H3; NbExp=3; IntAct=EBI-351935, EBI-11952806;
CC       P02545; Q9BZ95-3: NSD3; NbExp=3; IntAct=EBI-351935, EBI-22002759;
CC       P02545; Q6X4W1-6: NSMF; NbExp=3; IntAct=EBI-351935, EBI-25842707;
CC       P02545; O75694: NUP155; NbExp=6; IntAct=EBI-351935, EBI-1050769;
CC       P02545; Q3SX64: ODF3L2; NbExp=3; IntAct=EBI-351935, EBI-6660184;
CC       P02545; Q96RG2: PASK; NbExp=2; IntAct=EBI-351935, EBI-1042651;
CC       P02545; Q9HBE1-4: PATZ1; NbExp=3; IntAct=EBI-351935, EBI-11022007;
CC       P02545; Q96FA3: PELI1; NbExp=3; IntAct=EBI-351935, EBI-448369;
CC       P02545; O75925: PIAS1; NbExp=3; IntAct=EBI-351935, EBI-629434;
CC       P02545; Q03181-2: PPARD; NbExp=3; IntAct=EBI-351935, EBI-10223258;
CC       P02545; Q9NWB1-5: RBFOX1; NbExp=3; IntAct=EBI-351935, EBI-12123390;
CC       P02545; Q8TCX5: RHPN1; NbExp=3; IntAct=EBI-351935, EBI-746325;
CC       P02545; Q8WVD3: RNF138; NbExp=3; IntAct=EBI-351935, EBI-749039;
CC       P02545; P62701: RPS4X; NbExp=3; IntAct=EBI-351935, EBI-354303;
CC       P02545; Q6ZNE9: RUFY4; NbExp=3; IntAct=EBI-351935, EBI-10181525;
CC       P02545; Q8N488: RYBP; NbExp=3; IntAct=EBI-351935, EBI-752324;
CC       P02545; Q8IYM2: SLFN12; NbExp=3; IntAct=EBI-351935, EBI-2822550;
CC       P02545; Q13573: SNW1; NbExp=4; IntAct=EBI-351935, EBI-632715;
CC       P02545; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-351935, EBI-5235340;
CC       P02545; Q7Z698: SPRED2; NbExp=3; IntAct=EBI-351935, EBI-7082156;
CC       P02545; O75886: STAM2; NbExp=3; IntAct=EBI-351935, EBI-373258;
CC       P02545; Q9UNE7: STUB1; NbExp=3; IntAct=EBI-351935, EBI-357085;
CC       P02545; Q9UH99: SUN2; NbExp=4; IntAct=EBI-351935, EBI-1044964;
CC       P02545; Q8WXH0-1: SYNE2; NbExp=3; IntAct=EBI-351935, EBI-6170976;
CC       P02545; P54274-2: TERF1; NbExp=3; IntAct=EBI-351935, EBI-711018;
CC       P02545; P42166: TMPO; NbExp=4; IntAct=EBI-351935, EBI-395393;
CC       P02545; Q96KP6: TNIP3; NbExp=3; IntAct=EBI-351935, EBI-2509913;
CC       P02545; Q86WT6-2: TRIM69; NbExp=3; IntAct=EBI-351935, EBI-11525489;
CC       P02545; Q5VYS8-5: TUT7; NbExp=3; IntAct=EBI-351935, EBI-9088812;
CC       P02545; Q04323-2: UBXN1; NbExp=3; IntAct=EBI-351935, EBI-11530712;
CC       P02545; Q9Y4E8-2: USP15; NbExp=3; IntAct=EBI-351935, EBI-12041225;
CC       P02545; Q70EL1-9: USP54; NbExp=3; IntAct=EBI-351935, EBI-11975223;
CC       P02545; Q93009: USP7; NbExp=4; IntAct=EBI-351935, EBI-302474;
CC       P02545; P63104: YWHAZ; NbExp=2; IntAct=EBI-351935, EBI-347088;
CC       P02545; P10074: ZBTB48; NbExp=3; IntAct=EBI-351935, EBI-744864;
CC       P02545; Q6ZN57: ZFP2; NbExp=3; IntAct=EBI-351935, EBI-7236323;
CC       P02545; Q8WW38: ZFPM2; NbExp=3; IntAct=EBI-351935, EBI-947213;
CC       P02545; Q15776: ZKSCAN8; NbExp=3; IntAct=EBI-351935, EBI-2602314;
CC       P02545; P17024: ZNF20; NbExp=3; IntAct=EBI-351935, EBI-717634;
CC       P02545; Q14585: ZNF345; NbExp=3; IntAct=EBI-351935, EBI-2818408;
CC       P02545; Q9C0F3: ZNF436; NbExp=3; IntAct=EBI-351935, EBI-8489702;
CC       P02545; Q8N0Y2-2: ZNF444; NbExp=3; IntAct=EBI-351935, EBI-12010736;
CC       P02545; Q96MN9-2: ZNF488; NbExp=3; IntAct=EBI-351935, EBI-25831733;
CC       P02545; Q6ZNH5: ZNF497; NbExp=3; IntAct=EBI-351935, EBI-10486136;
CC       P02545; Q8TBZ8: ZNF564; NbExp=3; IntAct=EBI-351935, EBI-10273713;
CC       P02545; Q7Z3I7: ZNF572; NbExp=3; IntAct=EBI-351935, EBI-10172590;
CC       P02545; Q96LX8: ZNF597; NbExp=3; IntAct=EBI-351935, EBI-9091553;
CC       P02545; Q9BS31: ZNF649; NbExp=3; IntAct=EBI-351935, EBI-4395789;
CC       P02545; O43309: ZSCAN12; NbExp=3; IntAct=EBI-351935, EBI-1210440;
CC       P02545; P10073: ZSCAN22; NbExp=3; IntAct=EBI-351935, EBI-10178224;
CC       P02545; P10215: NEC1; Xeno; NbExp=2; IntAct=EBI-351935, EBI-7183650;
CC       P02545; P10218: NEC2; Xeno; NbExp=2; IntAct=EBI-351935, EBI-7183680;
CC       P02545-1; P50402: EMD; NbExp=4; IntAct=EBI-351949, EBI-489887;
CC       P02545-1; P20700: LMNB1; NbExp=5; IntAct=EBI-351949, EBI-968218;
CC       P02545-1; PRO_0000314029 [P36956]: SREBF1; NbExp=6; IntAct=EBI-351949, EBI-22057616;
CC       P02545-1; O75844: ZMPSTE24; NbExp=2; IntAct=EBI-351949, EBI-1056377;
CC       P02545-2; Q9HC96: CAPN10; NbExp=3; IntAct=EBI-351953, EBI-3915761;
CC       P02545-2; Q9UNS2: COPS3; NbExp=3; IntAct=EBI-351953, EBI-350590;
CC       P02545-2; Q0D2I5: IFFO1; NbExp=2; IntAct=EBI-351953, EBI-742894;
CC       P02545-2; P02545-2: LMNA; NbExp=4; IntAct=EBI-351953, EBI-351953;
CC       P02545-2; P20700: LMNB1; NbExp=19; IntAct=EBI-351953, EBI-968218;
CC       P02545-2; O75925: PIAS1; NbExp=3; IntAct=EBI-351953, EBI-629434;
CC       P02545-2; Q8N0S2: SYCE1; NbExp=3; IntAct=EBI-351953, EBI-6872807;
CC       P02545-2; Q9GZS3: WDR61; NbExp=3; IntAct=EBI-351953, EBI-358545;
CC       P02545-6; Q71DI3: H3C15; NbExp=3; IntAct=EBI-9034379, EBI-750650;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:15372542,
CC       ECO:0000269|PubMed:31548606}. Nucleus envelope
CC       {ECO:0000269|PubMed:29599122}. Nucleus lamina
CC       {ECO:0000305|PubMed:10080180}. Nucleus, nucleoplasm. Nucleus matrix
CC       {ECO:0000269|PubMed:31548606}. Note=Farnesylation of prelamin-A/C
CC       facilitates nuclear envelope targeting and subsequent cleavage by
CC       ZMPSTE24/FACE1 to remove the farnesyl group produces mature lamin-A/C,
CC       which can then be inserted into the nuclear lamina (PubMed:15317753).
CC       EMD is required for proper localization of non-farnesylated prelamin-
CC       A/C (PubMed:19323649). {ECO:0000269|PubMed:15317753,
CC       ECO:0000269|PubMed:19323649}.
CC   -!- SUBCELLULAR LOCATION: [Isoform C]: Nucleus speckle
CC       {ECO:0000269|PubMed:16061563}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC       Name=A; Synonyms=Lamin A;
CC         IsoId=P02545-1; Sequence=Displayed;
CC       Name=C; Synonyms=Lamin C;
CC         IsoId=P02545-2; Sequence=VSP_002469, VSP_002470;
CC       Name=ADelta10; Synonyms=Lamin ADelta10;
CC         IsoId=P02545-3; Sequence=VSP_002468;
CC       Name=4;
CC         IsoId=P02545-4; Sequence=VSP_045977, VSP_045978, VSP_045979;
CC       Name=5;
CC         IsoId=P02545-5; Sequence=VSP_053503, VSP_053504;
CC       Name=6; Synonyms=Progerin;
CC         IsoId=P02545-6; Sequence=VSP_053505;
CC   -!- TISSUE SPECIFICITY: In the arteries, prelamin-A/C accumulation is not
CC       observed in young healthy vessels but is prevalent in medial vascular
CC       smooth muscle cells (VSMCs) from aged individuals and in
CC       atherosclerotic lesions, where it often colocalizes with senescent and
CC       degenerate VSMCs. Prelamin-A/C expression increases with age and
CC       disease. In normal aging, the accumulation of prelamin-A/C is caused in
CC       part by the down-regulation of ZMPSTE24/FACE1 in response to oxidative
CC       stress. {ECO:0000269|PubMed:20458013}.
CC   -!- PTM: Proteolytic cleavage of the C-terminal of 18 residues of prelamin-
CC       A/C results in the production of lamin-A/C (PubMed:20458013,
CC       PubMed:8175923, PubMed:9030603). The prelamin-A/C maturation pathway
CC       includes farnesylation of CAAX motif by protein farnesyltransferase
CC       (FNTA and FNTB), removal of the last three amino acids (-AAX) by
CC       RCE1/FACE2 and/or ZMPSTE24, methylation of the C-terminal cysteine by
CC       ICMT and endoproteolytic removal of the last 15 C-terminal amino acids
CC       by ZMPSTE24 (PubMed:20458013, PubMed:8175923, PubMed:9030603).
CC       Proteolytic cleavage requires prior farnesylation and methylation, and
CC       absence of these blocks cleavage (PubMed:20458013, PubMed:8175923,
CC       PubMed:9030603). {ECO:0000269|PubMed:20458013,
CC       ECO:0000269|PubMed:8175923, ECO:0000269|PubMed:9030603}.
CC   -!- PTM: Farnesylation of prelamin-A/C facilitates nuclear envelope
CC       targeting. {ECO:0000269|PubMed:15317753, ECO:0000269|PubMed:22355414}.
CC   -!- PTM: Increased phosphorylation of the lamins occurs before envelope
CC       disintegration and probably plays a role in regulating lamin
CC       associations. Phosphorylation status of S-22 determines its
CC       localization between double-strand break (DSB) sites and the nuclear
CC       matrix (PubMed:31548606). {ECO:0000269|PubMed:31548606,
CC       ECO:0000269|Ref.9}.
CC   -!- PTM: Sumoylation is necessary for the localization to the nuclear
CC       envelope. {ECO:0000269|PubMed:18606848}.
CC   -!- DISEASE: Emery-Dreifuss muscular dystrophy 2, autosomal dominant
CC       (EDMD2) [MIM:181350]: A form of Emery-Dreifuss muscular dystrophy, a
CC       degenerative myopathy characterized by weakness and atrophy of muscle
CC       without involvement of the nervous system, early contractures of the
CC       elbows, Achilles tendons and spine, and cardiomyopathy associated with
CC       cardiac conduction defects. {ECO:0000269|PubMed:22431096,
CC       ECO:0000269|PubMed:27234031}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Emery-Dreifuss muscular dystrophy 3, autosomal recessive
CC       (EDMD3) [MIM:616516]: A form of Emery-Dreifuss muscular dystrophy, a
CC       degenerative myopathy characterized by weakness and atrophy of muscle
CC       without involvement of the nervous system, early contractures of the
CC       elbows, Achilles tendons and spine, and cardiomyopathy associated with
CC       cardiac conduction defects. {ECO:0000269|PubMed:22431096,
CC       ECO:0000269|PubMed:27234031}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Cardiomyopathy, dilated, 1A (CMD1A) [MIM:115200]: A disorder
CC       characterized by ventricular dilation and impaired systolic function,
CC       resulting in congestive heart failure and arrhythmia. Patients are at
CC       risk of premature death. {ECO:0000269|PubMed:10580070,
CC       ECO:0000269|PubMed:11561226, ECO:0000269|PubMed:11792809,
CC       ECO:0000269|PubMed:11897440, ECO:0000269|PubMed:12486434,
CC       ECO:0000269|PubMed:12628721, ECO:0000269|PubMed:12920062,
CC       ECO:0000269|PubMed:14675861, ECO:0000269|PubMed:14684700,
CC       ECO:0000269|PubMed:15140538, ECO:0000269|PubMed:15219508,
CC       ECO:0000269|PubMed:15372542, ECO:0000269|PubMed:16061563,
CC       ECO:0000269|PubMed:18606848, ECO:0000269|PubMed:19167105,
CC       ECO:0000269|PubMed:20160190, ECO:0000269|PubMed:21846512}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Lipodystrophy, familial partial, 2 (FPLD2) [MIM:151660]: A
CC       disorder characterized by the loss of subcutaneous adipose tissue in
CC       the lower parts of the body (limbs, buttocks, trunk). It is accompanied
CC       by an accumulation of adipose tissue in the face and neck causing a
CC       double chin, fat neck, or cushingoid appearance. Adipose tissue may
CC       also accumulate in the axillae, back, labia majora, and intraabdominal
CC       region. Affected patients are insulin-resistant and may develop glucose
CC       intolerance and diabetes mellitus after age 20 years,
CC       hypertriglyceridemia, and low levels of high density lipoprotein
CC       cholesterol. {ECO:0000269|PubMed:10587585, ECO:0000269|PubMed:10655060,
CC       ECO:0000269|PubMed:10739751, ECO:0000269|PubMed:11792809,
CC       ECO:0000269|PubMed:12015247, ECO:0000269|PubMed:12196663,
CC       ECO:0000269|PubMed:12629077, ECO:0000269|PubMed:15372542,
CC       ECO:0000269|PubMed:17250669, ECO:0000269|PubMed:19220582,
CC       ECO:0000269|PubMed:24485160}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Charcot-Marie-Tooth disease, axonal, 2B1 (CMT2B1)
CC       [MIM:605588]: A recessive axonal form of Charcot-Marie-Tooth disease, a
CC       disorder of the peripheral nervous system, characterized by progressive
CC       weakness and atrophy, initially of the peroneal muscles and later of
CC       the distal muscles of the arms. Charcot-Marie-Tooth disease is
CC       classified in two main groups on the basis of electrophysiologic
CC       properties and histopathology: primary peripheral demyelinating
CC       neuropathies (designated CMT1 when they are dominantly inherited) and
CC       primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2
CC       group are characterized by signs of axonal degeneration in the absence
CC       of obvious myelin alterations, normal or slightly reduced nerve
CC       conduction velocities, and progressive distal muscle weakness and
CC       atrophy. {ECO:0000269|PubMed:11799477}. Note=The disease is caused by
CC       variants affecting the gene represented in this entry.
CC   -!- DISEASE: Hutchinson-Gilford progeria syndrome (HGPS) [MIM:176670]: Rare
CC       genetic disorder characterized by features reminiscent of marked
CC       premature aging. {ECO:0000269|PubMed:12714972,
CC       ECO:0000269|PubMed:12768443, ECO:0000269|PubMed:12927431,
CC       ECO:0000269|PubMed:15060110, ECO:0000269|PubMed:15286156,
CC       ECO:0000269|PubMed:15622532, ECO:0000269|PubMed:19933576,
CC       ECO:0000269|PubMed:21791255, ECO:0000269|PubMed:22355414,
CC       ECO:0000269|PubMed:23666920}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry. HGPS is caused by the
CC       toxic accumulation of a truncated form of lamin-A/C. This mutant
CC       protein, called progerin (isoform 6), acts to deregulate mitosis and
CC       DNA damage signaling, leading to premature cell death and senescence.
CC       The mutant form is mainly generated by a silent or missense mutation at
CC       codon 608 of prelamin A that causes activation of a cryptic splice
CC       donor site, resulting in production of isoform 6 with a deletion of 50
CC       amino acids near the C terminus. Progerin lacks the conserved
CC       ZMPSTE24/FACE1 cleavage site and therefore remains permanently
CC       farnesylated. Thus, although it can enter the nucleus and associate
CC       with the nuclear envelope, it cannot incorporate normally into the
CC       nuclear lamina (PubMed:12714972). {ECO:0000269|PubMed:12714972}.
CC   -!- DISEASE: Cardiomyopathy, dilated, with hypergonadotropic hypogonadism
CC       (CMDHH) [MIM:212112]: A disorder characterized by the association of
CC       genital anomalies, hypergonadotropic hypogonadism and dilated
CC       cardiomyopathy. Patients can present other variable clinical
CC       manifestations including intellectual disability, skeletal anomalies,
CC       scleroderma-like skin, graying and thinning of hair, osteoporosis.
CC       Dilated cardiomyopathy is characterized by ventricular dilation and
CC       impaired systolic function, resulting in congestive heart failure and
CC       arrhythmia. {ECO:0000269|PubMed:12927431, ECO:0000269|PubMed:17150192,
CC       ECO:0000269|PubMed:19283854}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Mandibuloacral dysplasia with type A lipodystrophy (MADA)
CC       [MIM:248370]: A form of mandibuloacral dysplasia, a rare progeroid
CC       disorder with clinical and genetic heterogeneity, characterized by
CC       growth retardation, craniofacial dysmorphic features due to distal bone
CC       resorption, musculoskeletal and skin abnormalities associated with
CC       lipodystrophy. MADA is an autosomal recessive disease characterized by
CC       mandibular and clavicular hypoplasia, acroosteolysis, delayed closure
CC       of the cranial suture, progeroid appearance, partial alopecia, soft
CC       tissue calcinosis, joint contractures, and partial lipodystrophy with
CC       loss of subcutaneous fat from the extremities. Adipose tissue in the
CC       face, neck and trunk is normal or increased.
CC       {ECO:0000269|PubMed:12075506, ECO:0000269|PubMed:15998779,
CC       ECO:0000269|PubMed:16278265}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Restrictive dermopathy 2 (RSDM2) [MIM:619793]: An autosomal
CC       dominant form of restrictive dermopathy, a genodermatosis mainly
CC       characterized by intrauterine growth retardation, tight and rigid skin
CC       with erosions, prominent superficial vasculature and epidermal
CC       hyperkeratosis, facial dysmorphism, sparse/absent eyelashes and
CC       eyebrows, mineralization defects of the skull, thin dysplastic
CC       clavicles, pulmonary hypoplasia, multiple joint contractures and an
CC       early neonatal lethal course. Liveborn children usually die within the
CC       first week of life. {ECO:0000269|PubMed:15317753}. Note=The disease is
CC       caused by variants affecting the gene represented in this entry.
CC   -!- DISEASE: Heart-hand syndrome Slovenian type (HHS-Slovenian)
CC       [MIM:610140]: Heart-hand syndrome (HHS) is a clinically and genetically
CC       heterogeneous disorder characterized by the co-occurrence of a
CC       congenital cardiac disease and limb malformations.
CC       {ECO:0000269|PubMed:18611980}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Muscular dystrophy congenital LMNA-related (MDCL)
CC       [MIM:613205]: A form of congenital muscular dystrophy. Patients present
CC       at birth, or within the first few months of life, with hypotonia,
CC       muscle weakness and often with joint contractures.
CC       {ECO:0000269|PubMed:18551513}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Note=Defects in LMNA may cause a late-onset cardiocutaneous
CC       progeria syndrome characterized by cutaneous manifestations of aging
CC       appearing in the third decade of life, cardiac valve calcification and
CC       dysfunction, prominent atherosclerosis, and cardiomyopathy, leading to
CC       death on average in the fourth decade. {ECO:0000269|PubMed:23666920}.
CC   -!- MISCELLANEOUS: There are three types of lamins in human cells: A, B,
CC       and C.
CC   -!- MISCELLANEOUS: The structural integrity of the lamina is strictly
CC       controlled by the cell cycle, as seen by the disintegration and
CC       formation of the nuclear envelope in prophase and telophase,
CC       respectively.
CC   -!- MISCELLANEOUS: [Isoform 6]: Disease-associated isoform. Polymorphism at
CC       codon 608 results in activation of a cryptic splice donor site within
CC       exon 11, resulting in a truncated protein product that lacks the site
CC       for endoproteolytic cleavage. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the intermediate filament family.
CC       {ECO:0000255|PROSITE-ProRule:PRU01188}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA27173.1; Type=Frameshift; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Human Intermediate Filament Mutation Database;
CC       URL="http://www.interfil.org";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X03444; CAA27173.1; ALT_FRAME; mRNA.
DR   EMBL; X03445; CAA27174.1; -; mRNA.
DR   EMBL; M13451; AAA36164.1; -; mRNA.
DR   EMBL; M13452; AAA36160.1; -; mRNA.
DR   EMBL; AY847597; AAW32540.1; -; mRNA.
DR   EMBL; AY847595; AAW32538.1; -; mRNA.
DR   EMBL; AY357727; AAR29466.1; -; mRNA.
DR   EMBL; AK295390; BAG58344.1; -; mRNA.
DR   EMBL; AL135927; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL355388; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL356734; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471121; EAW52997.1; -; Genomic_DNA.
DR   EMBL; CH471121; EAW52999.1; -; Genomic_DNA.
DR   EMBL; BC000511; AAH00511.1; -; mRNA.
DR   EMBL; BC003162; AAH03162.1; -; mRNA.
DR   EMBL; BC014507; AAH14507.1; -; mRNA.
DR   EMBL; AF381029; AAK59326.1; -; mRNA.
DR   CCDS; CCDS1129.1; -. [P02545-1]
DR   CCDS; CCDS1131.1; -. [P02545-2]
DR   CCDS; CCDS58038.1; -. [P02545-4]
DR   CCDS; CCDS72941.1; -. [P02545-6]
DR   PIR; A02961; VEHULA.
DR   PIR; A02962; VEHULC.
DR   RefSeq; NP_001244303.1; NM_001257374.2. [P02545-4]
DR   RefSeq; NP_001269553.1; NM_001282624.1.
DR   RefSeq; NP_001269554.1; NM_001282625.1. [P02545-2]
DR   RefSeq; NP_001269555.1; NM_001282626.1. [P02545-6]
DR   RefSeq; NP_005563.1; NM_005572.3. [P02545-2]
DR   RefSeq; NP_733821.1; NM_170707.3. [P02545-1]
DR   RefSeq; NP_733822.1; NM_170708.3. [P02545-3]
DR   PDB; 1IFR; X-ray; 1.40 A; A=436-552.
DR   PDB; 1IVT; NMR; -; A=428-549.
DR   PDB; 1X8Y; X-ray; 2.20 A; A=305-387.
DR   PDB; 2XV5; X-ray; 2.40 A; A/B=328-398.
DR   PDB; 2YPT; X-ray; 3.80 A; F/G/H/I=661-664.
DR   PDB; 3GEF; X-ray; 1.50 A; A/B/C/D=436-552.
DR   PDB; 3V4Q; X-ray; 3.06 A; A=313-386.
DR   PDB; 3V4W; X-ray; 3.70 A; A=313-386.
DR   PDB; 3V5B; X-ray; 3.00 A; A=313-386.
DR   PDB; 6GHD; X-ray; 2.10 A; B/F=428-546.
DR   PDB; 6JLB; X-ray; 3.21 A; A/B/C/D=1-300.
DR   PDB; 6RPR; X-ray; 2.26 A; B=430-545.
DR   PDB; 6SNZ; X-ray; 2.60 A; A/B/C/D=65-222.
DR   PDB; 6YF5; X-ray; 1.83 A; A/B/C/D=17-70.
DR   PDB; 6YJD; X-ray; 2.90 A; A=329-403.
DR   PDB; 7CRG; X-ray; 1.80 A; A/B/C=406-553.
DR   PDB; 7D9N; X-ray; 3.70 A; A/B=27-229.
DR   PDB; 7X5D; X-ray; 1.82 A; A/B=244-339.
DR   PDB; 7Z21; X-ray; 1.63 A; E/F=411-566.
DR   PDBsum; 1IFR; -.
DR   PDBsum; 1IVT; -.
DR   PDBsum; 1X8Y; -.
DR   PDBsum; 2XV5; -.
DR   PDBsum; 2YPT; -.
DR   PDBsum; 3GEF; -.
DR   PDBsum; 3V4Q; -.
DR   PDBsum; 3V4W; -.
DR   PDBsum; 3V5B; -.
DR   PDBsum; 6GHD; -.
DR   PDBsum; 6JLB; -.
DR   PDBsum; 6RPR; -.
DR   PDBsum; 6SNZ; -.
DR   PDBsum; 6YF5; -.
DR   PDBsum; 6YJD; -.
DR   PDBsum; 7CRG; -.
DR   PDBsum; 7D9N; -.
DR   PDBsum; 7X5D; -.
DR   PDBsum; 7Z21; -.
DR   AlphaFoldDB; P02545; -.
DR   BMRB; P02545; -.
DR   SMR; P02545; -.
DR   BioGRID; 110186; 1225.
DR   CORUM; P02545; -.
DR   DIP; DIP-32948N; -.
DR   DIP; DIP-58162N; -.
DR   IntAct; P02545; 367.
DR   MINT; P02545; -.
DR   STRING; 9606.ENSP00000357283; -.
DR   ChEMBL; CHEMBL1293235; -.
DR   GlyConnect; 2876; 1 O-GlcNAc glycan (2 sites). [P02545-3]
DR   GlyCosmos; P02545; 12 sites, 2 glycans.
DR   GlyGen; P02545; 25 sites, 2 O-linked glycans (25 sites).
DR   iPTMnet; P02545; -.
DR   MetOSite; P02545; -.
DR   PhosphoSitePlus; P02545; -.
DR   SwissPalm; P02545; -.
DR   BioMuta; LMNA; -.
DR   DMDM; 125962; -.
DR   REPRODUCTION-2DPAGE; IPI00021405; -.
DR   REPRODUCTION-2DPAGE; IPI00216952; -.
DR   REPRODUCTION-2DPAGE; P02545; -.
DR   SWISS-2DPAGE; P02545; -.
DR   CPTAC; CPTAC-399; -.
DR   CPTAC; CPTAC-400; -.
DR   CPTAC; CPTAC-973; -.
DR   CPTAC; CPTAC-974; -.
DR   EPD; P02545; -.
DR   jPOST; P02545; -.
DR   MassIVE; P02545; -.
DR   MaxQB; P02545; -.
DR   PaxDb; P02545; -.
DR   PeptideAtlas; P02545; -.
DR   PRIDE; P02545; -.
DR   ProteomicsDB; 13394; -.
DR   ProteomicsDB; 18441; -.
DR   ProteomicsDB; 51530; -. [P02545-1]
DR   ProteomicsDB; 51531; -. [P02545-2]
DR   ProteomicsDB; 51532; -. [P02545-3]
DR   ProteomicsDB; 67698; -.
DR   TopDownProteomics; P02545-1; -. [P02545-1]
DR   TopDownProteomics; P02545-2; -. [P02545-2]
DR   TopDownProteomics; P02545-4; -. [P02545-4]
DR   Antibodypedia; 1676; 1765 antibodies from 49 providers.
DR   DNASU; 4000; -.
DR   Ensembl; ENST00000361308.9; ENSP00000355292.6; ENSG00000160789.24. [P02545-1]
DR   Ensembl; ENST00000368299.7; ENSP00000357282.3; ENSG00000160789.24. [P02545-6]
DR   Ensembl; ENST00000368300.9; ENSP00000357283.4; ENSG00000160789.24. [P02545-1]
DR   Ensembl; ENST00000368301.6; ENSP00000357284.2; ENSG00000160789.24. [P02545-2]
DR   Ensembl; ENST00000448611.6; ENSP00000395597.2; ENSG00000160789.24. [P02545-4]
DR   Ensembl; ENST00000473598.6; ENSP00000421821.1; ENSG00000160789.24. [P02545-5]
DR   Ensembl; ENST00000675939.1; ENSP00000502256.1; ENSG00000160789.24. [P02545-1]
DR   Ensembl; ENST00000676385.2; ENSP00000502091.1; ENSG00000160789.24. [P02545-3]
DR   Ensembl; ENST00000677389.1; ENSP00000503633.1; ENSG00000160789.24. [P02545-2]
DR   Ensembl; ENST00000682650.1; ENSP00000506904.1; ENSG00000160789.24. [P02545-3]
DR   Ensembl; ENST00000683032.1; ENSP00000506771.1; ENSG00000160789.24. [P02545-1]
DR   GeneID; 4000; -.
DR   KEGG; hsa:4000; -.
DR   MANE-Select; ENST00000368300.9; ENSP00000357283.4; NM_170707.4; NP_733821.1.
DR   UCSC; uc001fnf.3; human. [P02545-1]
DR   AGR; HGNC:6636; -.
DR   CTD; 4000; -.
DR   DisGeNET; 4000; -.
DR   GeneCards; LMNA; -.
DR   GeneReviews; LMNA; -.
DR   HGNC; HGNC:6636; LMNA.
DR   HPA; ENSG00000160789; Low tissue specificity.
DR   MalaCards; LMNA; -.
DR   MIM; 115200; phenotype.
DR   MIM; 150330; gene.
DR   MIM; 151660; phenotype.
DR   MIM; 176670; phenotype.
DR   MIM; 181350; phenotype.
DR   MIM; 212112; phenotype.
DR   MIM; 248370; phenotype.
DR   MIM; 605588; phenotype.
DR   MIM; 610140; phenotype.
DR   MIM; 613205; phenotype.
DR   MIM; 616516; phenotype.
DR   MIM; 619793; phenotype.
DR   neXtProt; NX_P02545; -.
DR   OpenTargets; ENSG00000160789; -.
DR   Orphanet; 79474; Atypical Werner syndrome.
DR   Orphanet; 98853; Autosomal dominant Emery-Dreifuss muscular dystrophy.
DR   Orphanet; 98855; Autosomal recessive Emery-Dreifuss muscular dystrophy.
DR   Orphanet; 280365; Autosomal semi-dominant severe lipodystrophic laminopathy.
DR   Orphanet; 98856; Charcot-Marie-Tooth disease type 2B1.
DR   Orphanet; 157973; Congenital muscular dystrophy due to LMNA mutation.
DR   Orphanet; 2229; Dilated cardiomyopathy-hypergonadotropic hypogonadism syndrome.
DR   Orphanet; 300751; Familial dilated cardiomyopathy with conduction defect due to LMNA mutation.
DR   Orphanet; 293899; Familial isolated arrhythmogenic ventricular dysplasia, biventricular form.
DR   Orphanet; 293888; Familial isolated arrhythmogenic ventricular dysplasia, left dominant form.
DR   Orphanet; 293910; Familial isolated arrhythmogenic ventricular dysplasia, right dominant form.
DR   Orphanet; 154; Familial isolated dilated cardiomyopathy.
DR   Orphanet; 2348; Familial partial lipodystrophy, Dunnigan type.
DR   Orphanet; 79084; Familial partial lipodystrophy, Koebberling type.
DR   Orphanet; 168796; Heart-hand syndrome, Slovenian type.
DR   Orphanet; 740; Hutchinson-Gilford progeria syndrome.
DR   Orphanet; 54260; Left ventricular noncompaction.
DR   Orphanet; 363618; LMNA-related cardiocutaneous progeria syndrome.
DR   Orphanet; 90153; Mandibuloacral dysplasia with type A lipodystrophy.
DR   Orphanet; 1662; Restrictive dermopathy.
DR   PharmGKB; PA231; -.
DR   VEuPathDB; HostDB:ENSG00000160789; -.
DR   eggNOG; KOG0977; Eukaryota.
DR   GeneTree; ENSGT00940000157244; -.
DR   HOGENOM; CLU_012560_9_1_1; -.
DR   InParanoid; P02545; -.
DR   OMA; DDPPITY; -.
DR   OrthoDB; 72418at2759; -.
DR   PhylomeDB; P02545; -.
DR   TreeFam; TF101181; -.
DR   PathwayCommons; P02545; -.
DR   Reactome; R-HSA-1221632; Meiotic synapsis. [P02545-2]
DR   Reactome; R-HSA-2980766; Nuclear Envelope Breakdown.
DR   Reactome; R-HSA-2995383; Initiation of Nuclear Envelope (NE) Reformation.
DR   Reactome; R-HSA-352238; Breakdown of the nuclear lamina. [P02545-1]
DR   Reactome; R-HSA-381038; XBP1(S) activates chaperone genes.
DR   Reactome; R-HSA-4419969; Depolymerisation of the Nuclear Lamina.
DR   Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions.
DR   Reactome; R-HSA-8862803; Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models. [P02545-1]
DR   SABIO-RK; P02545; -.
DR   SignaLink; P02545; -.
DR   SIGNOR; P02545; -.
DR   BioGRID-ORCS; 4000; 90 hits in 1163 CRISPR screens.
DR   ChiTaRS; LMNA; human.
DR   EvolutionaryTrace; P02545; -.
DR   GeneWiki; LMNA; -.
DR   GenomeRNAi; 4000; -.
DR   Pharos; P02545; Tbio.
DR   PRO; PR:P02545; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; P02545; protein.
DR   Bgee; ENSG00000160789; Expressed in nipple and 206 other tissues.
DR   ExpressionAtlas; P02545; baseline and differential.
DR   Genevisible; P02545; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005882; C:intermediate filament; TAS:UniProtKB.
DR   GO; GO:0005638; C:lamin filament; TAS:UniProtKB.
DR   GO; GO:0005635; C:nuclear envelope; IDA:UniProtKB.
DR   GO; GO:0005652; C:nuclear lamina; IBA:GO_Central.
DR   GO; GO:0016363; C:nuclear matrix; IDA:UniProtKB.
DR   GO; GO:0031965; C:nuclear membrane; HDA:UniProtKB.
DR   GO; GO:0016607; C:nuclear speck; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:CAFA.
DR   GO; GO:0005634; C:nucleus; IDA:ARUK-UCL.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0035861; C:site of double-strand break; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0005200; F:structural constituent of cytoskeleton; IBA:GO_Central.
DR   GO; GO:0005198; F:structural molecule activity; TAS:UniProtKB.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEP:UniProtKB.
DR   GO; GO:0090398; P:cellular senescence; IDA:GO_Central.
DR   GO; GO:1990683; P:DNA double-strand break attachment to nuclear envelope; IDA:UniProtKB.
DR   GO; GO:0030951; P:establishment or maintenance of microtubule cytoskeleton polarity; ISS:BHF-UCL.
DR   GO; GO:0031507; P:heterochromatin formation; IBA:GO_Central.
DR   GO; GO:0007517; P:muscle organ development; IMP:UniProtKB.
DR   GO; GO:1903243; P:negative regulation of cardiac muscle hypertrophy in response to stress; ISS:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IMP:CAFA.
DR   GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:0072201; P:negative regulation of mesenchymal cell proliferation; IEA:Ensembl.
DR   GO; GO:0090201; P:negative regulation of release of cytochrome c from mitochondria; IEA:Ensembl.
DR   GO; GO:0006998; P:nuclear envelope organization; IMP:CAFA.
DR   GO; GO:0007097; P:nuclear migration; IBA:GO_Central.
DR   GO; GO:0051664; P:nuclear pore localization; IBA:GO_Central.
DR   GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0006606; P:protein import into nucleus; IEA:Ensembl.
DR   GO; GO:0008104; P:protein localization; IMP:CAFA.
DR   GO; GO:0090435; P:protein localization to nuclear envelope; IBA:GO_Central.
DR   GO; GO:0034504; P:protein localization to nucleus; ISS:UniProtKB.
DR   GO; GO:0030334; P:regulation of cell migration; ISS:BHF-UCL.
DR   GO; GO:1900180; P:regulation of protein localization to nucleus; IEA:Ensembl.
DR   GO; GO:0031647; P:regulation of protein stability; IEA:Ensembl.
DR   GO; GO:0032204; P:regulation of telomere maintenance; IMP:BHF-UCL.
DR   GO; GO:0055015; P:ventricular cardiac muscle cell development; IEA:Ensembl.
DR   DisProt; DP00716; -.
DR   Gene3D; 1.20.5.170; -; 1.
DR   Gene3D; 2.60.40.1260; Lamin Tail domain; 1.
DR   Gene3D; 1.20.5.500; Single helix bin; 1.
DR   Gene3D; 1.20.5.1160; Vasodilator-stimulated phosphoprotein; 1.
DR   InterPro; IPR018039; IF_conserved.
DR   InterPro; IPR039008; IF_rod_dom.
DR   InterPro; IPR001322; Lamin_tail_dom.
DR   InterPro; IPR036415; Lamin_tail_dom_sf.
DR   PANTHER; PTHR45721; LAMIN DM0-RELATED; 1.
DR   PANTHER; PTHR45721:SF5; PRELAMIN-A/C; 1.
DR   Pfam; PF00038; Filament; 1.
DR   Pfam; PF00932; LTD; 1.
DR   SMART; SM01391; Filament; 1.
DR   SUPFAM; SSF64593; Intermediate filament protein, coiled coil region; 2.
DR   SUPFAM; SSF74853; Lamin A/C globular tail domain; 1.
DR   SUPFAM; SSF90257; Myosin rod fragments; 1.
DR   PROSITE; PS00226; IF_ROD_1; 1.
DR   PROSITE; PS51842; IF_ROD_2; 1.
DR   PROSITE; PS51841; LTD; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Cardiomyopathy;
KW   Charcot-Marie-Tooth disease; Coiled coil; Congenital muscular dystrophy;
KW   Direct protein sequencing; Disease variant;
KW   Emery-Dreifuss muscular dystrophy; Intermediate filament; Isopeptide bond;
KW   Limb-girdle muscular dystrophy; Lipoprotein; Methylation;
KW   Neurodegeneration; Neuropathy; Nucleus; Phosphoprotein; Prenylation;
KW   Reference proteome; Ubl conjugation.
FT   CHAIN           1..661
FT                   /note="Prelamin-A/C"
FT                   /id="PRO_0000398835"
FT   CHAIN           1..646
FT                   /note="Lamin-A/C"
FT                   /id="PRO_0000063810"
FT   PROPEP          647..661
FT                   /note="Removed in Lamin-A/C form"
FT                   /id="PRO_0000398836"
FT   PROPEP          662..664
FT                   /note="Removed in Prelamin-A/C form and in Lamin-A/C form"
FT                   /id="PRO_0000403442"
FT   DOMAIN          31..387
FT                   /note="IF rod"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01188"
FT   DOMAIN          428..545
FT                   /note="LTD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01187"
FT   REGION          1..130
FT                   /note="Interaction with MLIP"
FT                   /evidence="ECO:0000269|PubMed:21498514"
FT   REGION          1..33
FT                   /note="Head"
FT   REGION          1..25
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          34..70
FT                   /note="Coil 1A"
FT   REGION          71..80
FT                   /note="Linker 1"
FT   REGION          81..218
FT                   /note="Coil 1B"
FT   REGION          219..242
FT                   /note="Linker 2"
FT   REGION          243..383
FT                   /note="Coil 2"
FT   REGION          259..331
FT                   /note="Necessary and sufficient for the interaction with
FT                   IFFO1"
FT                   /evidence="ECO:0000269|PubMed:31548606"
FT   REGION          384..664
FT                   /note="Tail"
FT   REGION          384..442
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          552..576
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          598..619
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           417..422
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        391..417
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            266
FT                   /note="Heptad change of phase"
FT   SITE            325
FT                   /note="Stutter"
FT                   /evidence="ECO:0000305"
FT   SITE            330
FT                   /note="Heptad change of phase"
FT   SITE            646..647
FT                   /note="Cleavage; by endoprotease"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         3
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         12
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         18
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         19
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         22
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|Ref.9, ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         32
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P48678"
FT   MOD_RES         32
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P48678"
FT   MOD_RES         51
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         66
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         71
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         107
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         108
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         123
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P48678"
FT   MOD_RES         135
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P48678"
FT   MOD_RES         155
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P48678"
FT   MOD_RES         171
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P48678"
FT   MOD_RES         171
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P48678"
FT   MOD_RES         201
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P48678"
FT   MOD_RES         212
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         260
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P48678"
FT   MOD_RES         270
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         277
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         301
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         307
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         311
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         390
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         392
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         395
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         398
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         403
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         404
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:24275569"
FT   MOD_RES         407
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P48678"
FT   MOD_RES         414
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:24275569"
FT   MOD_RES         429
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         431
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         450
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         457
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P48678"
FT   MOD_RES         458
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         463
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         496
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P48679"
FT   MOD_RES         505
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         510
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P48679"
FT   MOD_RES         533
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         546
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P48678"
FT   MOD_RES         548
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P48678"
FT   MOD_RES         568
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P48678"
FT   MOD_RES         571
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P48678"
FT   MOD_RES         612
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         613
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         616
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P48678"
FT   MOD_RES         619
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         628
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:17924679, ECO:0007744|PubMed:18220336,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         632
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         636
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         652
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         661
FT                   /note="Cysteine methyl ester"
FT                   /evidence="ECO:0000269|PubMed:8175923,
FT                   ECO:0000269|PubMed:9030603"
FT   LIPID           661
FT                   /note="S-farnesyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:8175923,
FT                   ECO:0000269|PubMed:9030603"
FT   CROSSLNK        32
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        97
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:25772364, ECO:0007744|PubMed:28112733"
FT   CROSSLNK        171
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        201
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO); alternate"
FT   CROSSLNK        201
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        208
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        219
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        233
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25114211,
FT                   ECO:0007744|PubMed:25218447, ECO:0007744|PubMed:25755297,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        260
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25755297,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        270
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25755297,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        311
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:25772364, ECO:0007744|PubMed:28112733"
FT   CROSSLNK        366
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        378
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:25755297, ECO:0007744|PubMed:25772364,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        417
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:25755297, ECO:0007744|PubMed:28112733"
FT   CROSSLNK        420
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:25755297, ECO:0007744|PubMed:25772364,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        450
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        470
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        486
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        597
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        597
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211,
FT                   ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         1..99
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_053503"
FT   VAR_SEQ         1..7
FT                   /note="METPSQR -> MGNSEGC (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_045977"
FT   VAR_SEQ         8..119
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_045978"
FT   VAR_SEQ         100..119
FT                   /note="ARLQLELSKVREEFKELKAR -> MDLEAWDPHLEPDAEAMVDG (in
FT                   isoform 5)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_053504"
FT   VAR_SEQ         537..566
FT                   /note="Missing (in isoform ADelta10)"
FT                   /evidence="ECO:0000303|PubMed:8621584"
FT                   /id="VSP_002468"
FT   VAR_SEQ         567..572
FT                   /note="GSHCSS -> VSGSRR (in isoform C)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:3453101, ECO:0000303|PubMed:3462705"
FT                   /id="VSP_002469"
FT   VAR_SEQ         573..664
FT                   /note="Missing (in isoform C)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:3453101, ECO:0000303|PubMed:3462705"
FT                   /id="VSP_002470"
FT   VAR_SEQ         607..656
FT                   /note="Missing (in isoform 6)"
FT                   /evidence="ECO:0000303|Ref.4"
FT                   /id="VSP_053505"
FT   VAR_SEQ         664
FT                   /note="M -> IQEMGMRWEVEEGRRKVSLSCLP (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_045979"
FT   VARIANT         10
FT                   /note="T -> I (in an atypical progeroid patient; diagnosed
FT                   as Seip syndrome; unknown pathological significance;
FT                   dbSNP:rs57077886)"
FT                   /evidence="ECO:0000269|PubMed:15060110"
FT                   /id="VAR_039745"
FT   VARIANT         24
FT                   /note="T -> S (in EDMD3)"
FT                   /evidence="ECO:0000269|PubMed:27234031"
FT                   /id="VAR_076562"
FT   VARIANT         25
FT                   /note="R -> G (in EDMD2; dbSNP:rs58327533)"
FT                   /evidence="ECO:0000269|PubMed:14684700"
FT                   /id="VAR_039746"
FT   VARIANT         25
FT                   /note="R -> P (in EDMD2; mis-localized in the nucleus;
FT                   causes nuclear deformations and LMNB1 redistribution;
FT                   dbSNP:rs61578124)"
FT                   /evidence="ECO:0000269|PubMed:11503164,
FT                   ECO:0000269|PubMed:20848652"
FT                   /id="VAR_039747"
FT   VARIANT         28
FT                   /note="R -> W (in FPLD2; dbSNP:rs59914820)"
FT                   /evidence="ECO:0000269|PubMed:12015247"
FT                   /id="VAR_039748"
FT   VARIANT         32
FT                   /note="Missing (in EDMD2; abnormal nuclear localization in
FT                   a honeycomb expression pattern in about 11% of cultured
FT                   skin fibroblasts from heterozygous patients; no effect on
FT                   protein level)"
FT                   /evidence="ECO:0000269|PubMed:12467752,
FT                   ECO:0000269|PubMed:14684700, ECO:0000269|PubMed:15372542"
FT                   /id="VAR_039749"
FT   VARIANT         33
FT                   /note="E -> D (in CMT2; autosomal dominant form;
FT                   dbSNP:rs57966821)"
FT                   /evidence="ECO:0000269|PubMed:14985400"
FT                   /id="VAR_039750"
FT   VARIANT         33
FT                   /note="E -> G (in EDMD2; dbSNP:rs267607614)"
FT                   /evidence="ECO:0000269|PubMed:14985400"
FT                   /id="VAR_039751"
FT   VARIANT         35
FT                   /note="L -> V (in EDMD2; dbSNP:rs56694480)"
FT                   /evidence="ECO:0000269|PubMed:14684700"
FT                   /id="VAR_039752"
FT   VARIANT         39
FT                   /note="N -> S (in MDCL and EDMD2; dbSNP:rs57983345)"
FT                   /evidence="ECO:0000269|PubMed:18551513,
FT                   ECO:0000269|PubMed:20848652"
FT                   /id="VAR_063588"
FT   VARIANT         43
FT                   /note="A -> T (in EDMD2; dbSNP:rs60446065)"
FT                   /evidence="ECO:0000269|PubMed:11503164"
FT                   /id="VAR_039753"
FT   VARIANT         45
FT                   /note="Y -> C (in EDMD2; dbSNP:rs58436778)"
FT                   /evidence="ECO:0000269|PubMed:10939567,
FT                   ECO:0000269|PubMed:20848652"
FT                   /id="VAR_009971"
FT   VARIANT         50
FT                   /note="R -> P (in EDMD2 and MDCL; dbSNP:rs60695352)"
FT                   /evidence="ECO:0000269|PubMed:10939567,
FT                   ECO:0000269|PubMed:18551513"
FT                   /id="VAR_009972"
FT   VARIANT         50
FT                   /note="R -> S (in EDMD2; dbSNP:rs59931416)"
FT                   /evidence="ECO:0000269|PubMed:11503164"
FT                   /id="VAR_039754"
FT   VARIANT         57
FT                   /note="A -> P (in CMDHH; phenotype originally designated as
FT                   atypical Werner syndrome; dbSNP:rs28928903)"
FT                   /evidence="ECO:0000269|PubMed:12927431"
FT                   /id="VAR_017656"
FT   VARIANT         59
FT                   /note="L -> R (in CMDHH; dbSNP:rs58922911)"
FT                   /evidence="ECO:0000269|PubMed:17150192,
FT                   ECO:0000269|PubMed:19283854"
FT                   /id="VAR_064055"
FT   VARIANT         60
FT                   /note="R -> G (in CMD1A and FPLD2; interacts with itself
FT                   and with wild-type LMNA and LMNB1; no decrease in the
FT                   stability compared with wild-type; dbSNP:rs28928900)"
FT                   /evidence="ECO:0000269|PubMed:10580070,
FT                   ECO:0000269|PubMed:11792809, ECO:0000269|PubMed:12196663"
FT                   /id="VAR_034706"
FT   VARIANT         62
FT                   /note="R -> G (in FPLD2; dbSNP:rs56793579)"
FT                   /evidence="ECO:0000269|PubMed:12015247"
FT                   /id="VAR_039755"
FT   VARIANT         63
FT                   /note="I -> N (in EDMD2; dbSNP:rs57793737)"
FT                   /evidence="ECO:0000269|PubMed:12467752,
FT                   ECO:0000269|PubMed:12649505, ECO:0000269|PubMed:15744034"
FT                   /id="VAR_039756"
FT   VARIANT         63
FT                   /note="I -> S (in EDMD2; no effect on protein level; no
FT                   obvious effect on nuclear morphology in cultured skin
FT                   fibroblasts from heterozygous patients; dbSNP:rs57793737)"
FT                   /evidence="ECO:0000269|PubMed:10939567,
FT                   ECO:0000269|PubMed:15372542"
FT                   /id="VAR_009974"
FT   VARIANT         65
FT                   /note="E -> G (in EDMD2)"
FT                   /evidence="ECO:0000269|PubMed:14684700"
FT                   /id="VAR_039757"
FT   VARIANT         85
FT                   /note="L -> R (in CMD1A; interacts with itself and with
FT                   wild-type LMNA and LMNB1; no decrease in the stability
FT                   compared with wild-type; dbSNP:rs28933090)"
FT                   /evidence="ECO:0000269|PubMed:10580070,
FT                   ECO:0000269|PubMed:11792809"
FT                   /id="VAR_009975"
FT   VARIANT         89
FT                   /note="R -> L (in CMD1A; dramatically aberrant localization
FT                   with almost no nuclear rim staining and formation of
FT                   intranuclear foci; dbSNP:rs59040894)"
FT                   /evidence="ECO:0000269|PubMed:12628721,
FT                   ECO:0000269|PubMed:20160190"
FT                   /id="VAR_039758"
FT   VARIANT         92
FT                   /note="L -> F (in CMD1A; dbSNP:rs267607560)"
FT                   /evidence="ECO:0000269|PubMed:21846512"
FT                   /id="VAR_067257"
FT   VARIANT         97
FT                   /note="K -> E (in CMD1A; dbSNP:rs59065411)"
FT                   /evidence="ECO:0000269|PubMed:11897440"
FT                   /id="VAR_039759"
FT   VARIANT         101
FT                   /note="R -> P (in CMD1A; dramatically aberrant localization
FT                   with almost no nuclear rim staining and formation of
FT                   intranuclear foci; dbSNP:rs267607568)"
FT                   /evidence="ECO:0000269|PubMed:20160190"
FT                   /id="VAR_070174"
FT   VARIANT         112
FT                   /note="Missing (in EDMD2)"
FT                   /evidence="ECO:0000269|PubMed:10939567,
FT                   ECO:0000269|PubMed:14684700"
FT                   /id="VAR_009976"
FT   VARIANT         125
FT                   /note="G -> S (found in patients with atrial fibrillation;
FT                   unknown pathological significance; dbSNP:rs267607605)"
FT                   /evidence="ECO:0000269|PubMed:19427440"
FT                   /id="VAR_072817"
FT   VARIANT         133
FT                   /note="R -> L (in FPLD2; dbSNP:rs60864230)"
FT                   /evidence="ECO:0000269|PubMed:12629077"
FT                   /id="VAR_016913"
FT   VARIANT         133
FT                   /note="R -> P (in EDMD2; dbSNP:rs60864230)"
FT                   /evidence="ECO:0000269|PubMed:11503164"
FT                   /id="VAR_017657"
FT   VARIANT         138
FT                   /note="E -> K (in HGPS; might be associated with early and
FT                   severe strokes; dbSNP:rs267607649)"
FT                   /evidence="ECO:0000269|PubMed:21791255"
FT                   /id="VAR_070175"
FT   VARIANT         140
FT                   /note="L -> P (in EDMD2; dbSNP:rs60652225)"
FT                   /evidence="ECO:0000269|PubMed:12649505,
FT                   ECO:0000269|PubMed:15744034"
FT                   /id="VAR_039760"
FT   VARIANT         140
FT                   /note="L -> R (in HGPS; phenotype originally designated as
FT                   atypical Werner syndrome; dbSNP:rs60652225)"
FT                   /evidence="ECO:0000269|PubMed:12927431"
FT                   /id="VAR_017658"
FT   VARIANT         143
FT                   /note="S -> F (in HGPS; dbSNP:rs58912633)"
FT                   /evidence="ECO:0000269|PubMed:15622532"
FT                   /id="VAR_034707"
FT   VARIANT         143
FT                   /note="S -> P (in CMD1A; dbSNP:rs61661343)"
FT                   /evidence="ECO:0000269|PubMed:15140538"
FT                   /id="VAR_039761"
FT   VARIANT         145
FT                   /note="E -> K (in HGPS; atypical; dbSNP:rs60310264)"
FT                   /evidence="ECO:0000269|PubMed:12714972"
FT                   /id="VAR_017659"
FT   VARIANT         150
FT                   /note="T -> P (in EDMD2; dbSNP:rs58917027)"
FT                   /evidence="ECO:0000269|PubMed:10908904,
FT                   ECO:0000269|PubMed:20848652"
FT                   /id="VAR_039762"
FT   VARIANT         161
FT                   /note="E -> K (in CMD1A; dbSNP:rs28933093)"
FT                   /evidence="ECO:0000269|PubMed:12920062,
FT                   ECO:0000269|PubMed:21846512"
FT                   /id="VAR_017660"
FT   VARIANT         166
FT                   /note="R -> P (in CMD1A; dramatically aberrant localization
FT                   with almost no nuclear rim staining and formation of
FT                   intranuclear foci; dbSNP:rs267607570)"
FT                   /evidence="ECO:0000269|PubMed:20160190"
FT                   /id="VAR_070176"
FT   VARIANT         189
FT                   /note="R -> P (in EDMD2; found also in a patient with
FT                   limb-girdle muscular dystrophy; sporadic;
FT                   dbSNP:rs267607643)"
FT                   /evidence="ECO:0000269|PubMed:20848652"
FT                   /id="VAR_064962"
FT   VARIANT         190
FT                   /note="R -> Q (in EDMD2 and CMD1A; aberrant localization
FT                   with decreased nuclear rim staining and increased formation
FT                   of intranuclear foci; dbSNP:rs267607571)"
FT                   /evidence="ECO:0000269|PubMed:15744034,
FT                   ECO:0000269|PubMed:20160190"
FT                   /id="VAR_039763"
FT   VARIANT         190
FT                   /note="R -> RR (in EDMD2)"
FT                   /evidence="ECO:0000269|PubMed:20848652"
FT                   /id="VAR_064963"
FT   VARIANT         190
FT                   /note="R -> W (in CMD1A; dbSNP:rs59026483)"
FT                   /evidence="ECO:0000269|PubMed:11897440,
FT                   ECO:0000269|PubMed:15219508, ECO:0000269|PubMed:16061563"
FT                   /id="VAR_039764"
FT   VARIANT         192
FT                   /note="D -> G (in CMD1A; dramatically increases the size of
FT                   intranuclear speckles and reduces their number; this
FT                   phenotype is only partially reversed by coexpression of the
FT                   G-192 mutation and wild-type lamin-C; precludes insertion
FT                   of lamin-C into the nuclear envelope when co-transfected
FT                   with the G-192 LMNA; G-192 lamin-C expression totally
FT                   disrupts the SUMO1 pattern; dbSNP:rs57045855)"
FT                   /evidence="ECO:0000269|PubMed:16061563"
FT                   /id="VAR_039765"
FT   VARIANT         195
FT                   /note="N -> K (in CMD1A; dramatically aberrant localization
FT                   with decreased nuclear rim staining and formation of
FT                   intranuclear foci; distribution of endogenous LMNA, LMNB1
FT                   and LMNB2 are altered in cells expressing this mutant;
FT                   causes an increased loss of endogenous EMD from the nuclear
FT                   envelope; interacts with itself and with wild-type LMNA and
FT                   LMNB1; no decrease in the stability compared with
FT                   wild-type; dbSNP:rs28933091)"
FT                   /evidence="ECO:0000269|PubMed:10580070,
FT                   ECO:0000269|PubMed:11792809"
FT                   /id="VAR_009977"
FT   VARIANT         196..199
FT                   /note="RLQT -> S (in EDMD2)"
FT                   /evidence="ECO:0000269|PubMed:11503164"
FT                   /id="VAR_039766"
FT   VARIANT         203
FT                   /note="E -> G (in CMD1A; interacts with itself and with
FT                   wild-type LMNA and LMNB1; no decrease in the stability
FT                   compared with wild-type; decreased sumoylation; aberrant
FT                   localization with decreased nuclear rim staining and
FT                   formation of intranuclear foci; associated with increased
FT                   cell death; dbSNP:rs28933092)"
FT                   /evidence="ECO:0000269|PubMed:10580070,
FT                   ECO:0000269|PubMed:11792809, ECO:0000269|PubMed:18606848"
FT                   /id="VAR_009978"
FT   VARIANT         203
FT                   /note="E -> K (in CMD1A; decreased sumoylation; aberrant
FT                   localization with decreased nuclear rim staining and
FT                   formation of intranuclear foci; associated with increased
FT                   cell death; dbSNP:rs61195471)"
FT                   /evidence="ECO:0000269|PubMed:11561226,
FT                   ECO:0000269|PubMed:18606848, ECO:0000269|PubMed:20160190"
FT                   /id="VAR_039767"
FT   VARIANT         206
FT                   /note="F -> L (in EDMD2; dbSNP:rs267607629)"
FT                   /evidence="ECO:0000269|PubMed:20848652"
FT                   /id="VAR_064964"
FT   VARIANT         208
FT                   /note="Missing (in EDMD2; no obvious effect on nuclear
FT                   morphology in cultured skin fibroblasts from heterozygous
FT                   patients; no effect on protein level)"
FT                   /evidence="ECO:0000269|PubMed:10814726,
FT                   ECO:0000269|PubMed:15372542"
FT                   /id="VAR_034708"
FT   VARIANT         210
FT                   /note="I -> S (in CMD1A; dramatically aberrant localization
FT                   with almost no nuclear rim staining and increased formation
FT                   of intranuclear foci; dbSNP:rs267607572)"
FT                   /evidence="ECO:0000269|PubMed:20160190"
FT                   /id="VAR_070177"
FT   VARIANT         215
FT                   /note="L -> P (in CMD1A; aberrant localization with
FT                   decreased nuclear rim staining and formation of
FT                   intranuclear foci; dbSNP:rs61295588)"
FT                   /evidence="ECO:0000269|PubMed:12486434,
FT                   ECO:0000269|PubMed:20160190"
FT                   /id="VAR_039768"
FT   VARIANT         222
FT                   /note="H -> P (in EDMD2; dbSNP:rs58034145)"
FT                   /evidence="ECO:0000269|PubMed:10939567"
FT                   /id="VAR_039769"
FT   VARIANT         222
FT                   /note="H -> Y (in EDMD2; dbSNP:rs28928901)"
FT                   /evidence="ECO:0000269|PubMed:10739764"
FT                   /id="VAR_009979"
FT   VARIANT         225
FT                   /note="R -> Q (in EDMD3; dbSNP:rs199474724)"
FT                   /evidence="ECO:0000269|PubMed:22431096"
FT                   /id="VAR_067697"
FT   VARIANT         230
FT                   /note="D -> N (in FPLD2; dbSNP:rs61214927)"
FT                   /evidence="ECO:0000269|PubMed:17250669"
FT                   /id="VAR_039770"
FT   VARIANT         232
FT                   /note="G -> E (in EDMD2; dbSNP:rs57207746)"
FT                   /evidence="ECO:0000269|PubMed:10939567"
FT                   /id="VAR_039771"
FT   VARIANT         248
FT                   /note="L -> P (in EDMD2; dbSNP:rs58850446)"
FT                   /evidence="ECO:0000269|PubMed:14684700"
FT                   /id="VAR_039772"
FT   VARIANT         249
FT                   /note="R -> Q (in EDMD2; no obvious effect on nuclear
FT                   morphology in cultured skin fibroblasts from heterozygous
FT                   patients; no effect on protein level; dbSNP:rs59332535)"
FT                   /evidence="ECO:0000269|PubMed:10739764,
FT                   ECO:0000269|PubMed:10939567, ECO:0000269|PubMed:11503164,
FT                   ECO:0000269|PubMed:12032588, ECO:0000269|PubMed:12649505,
FT                   ECO:0000269|PubMed:14684700, ECO:0000269|PubMed:15372542,
FT                   ECO:0000269|PubMed:15744034, ECO:0000269|PubMed:20848652"
FT                   /id="VAR_009980"
FT   VARIANT         249
FT                   /note="R -> W (in MDCL and EDMD2; mislocalized in the
FT                   nucleus; causes nuclear deformations and LMNB1
FT                   redistribution; dbSNP:rs121912496)"
FT                   /evidence="ECO:0000269|PubMed:18551513,
FT                   ECO:0000269|PubMed:20848652"
FT                   /id="VAR_063589"
FT   VARIANT         259
FT                   /note="Y -> C (in EDMD2)"
FT                   /evidence="ECO:0000269|PubMed:27234031"
FT                   /id="VAR_076563"
FT   VARIANT         260
FT                   /note="K -> N (in CMDA1)"
FT                   /evidence="ECO:0000269|PubMed:16156025"
FT                   /id="VAR_039773"
FT   VARIANT         261
FT                   /note="Missing (in EDMD2)"
FT                   /evidence="ECO:0000269|PubMed:10908904,
FT                   ECO:0000269|PubMed:10939567, ECO:0000269|PubMed:11503164"
FT                   /id="VAR_009981"
FT   VARIANT         267
FT                   /note="Y -> C (in EDMD2; dbSNP:rs57048196)"
FT                   /evidence="ECO:0000269|PubMed:14684700"
FT                   /id="VAR_039774"
FT   VARIANT         268
FT                   /note="S -> P (in EDMD2; dbSNP:rs267607630)"
FT                   /evidence="ECO:0000269|PubMed:20848652"
FT                   /id="VAR_064965"
FT   VARIANT         271
FT                   /note="L -> P (in EDMD2; dbSNP:rs267607641)"
FT                   /evidence="ECO:0000269|PubMed:20848652"
FT                   /id="VAR_064966"
FT   VARIANT         294
FT                   /note="Q -> P (in EDMD2; dbSNP:rs61616775)"
FT                   /evidence="ECO:0000269|PubMed:10939567,
FT                   ECO:0000269|PubMed:20848652"
FT                   /id="VAR_009982"
FT   VARIANT         295
FT                   /note="S -> P (in EDMD2; dbSNP:rs267607633)"
FT                   /evidence="ECO:0000269|PubMed:20848652"
FT                   /id="VAR_064967"
FT   VARIANT         298
FT                   /note="R -> C (in CMT2B1; dbSNP:rs59885338)"
FT                   /evidence="ECO:0000269|PubMed:11799477"
FT                   /id="VAR_017661"
FT   VARIANT         300
FT                   /note="D -> G (in HGPS; atypical form with late onset;
FT                   abnormal nuclear morphology with single or multple blebs,
FT                   lobulation and occasional ringed or donut shaped nuclei;
FT                   dbSNP:rs79907212)"
FT                   /evidence="ECO:0000269|PubMed:23666920"
FT                   /id="VAR_070178"
FT   VARIANT         302
FT                   /note="L -> P (in MDCL; dbSNP:rs267607596)"
FT                   /evidence="ECO:0000269|PubMed:18551513"
FT                   /id="VAR_063590"
FT   VARIANT         303
FT                   /note="S -> P (in EDMD2; dbSNP:rs61527854)"
FT                   /evidence="ECO:0000269|PubMed:20848652"
FT                   /id="VAR_064968"
FT   VARIANT         317
FT                   /note="E -> K (in CMD1A; dbSNP:rs56816490)"
FT                   /evidence="ECO:0000269|PubMed:11897440,
FT                   ECO:0000269|PubMed:21846512"
FT                   /id="VAR_039775"
FT   VARIANT         318
FT                   /note="A -> T (in CMD1A; no effect on nuclear morphology
FT                   and lamin A localization; dbSNP:rs267607574)"
FT                   /evidence="ECO:0000269|PubMed:20160190"
FT                   /id="VAR_070179"
FT   VARIANT         336
FT                   /note="R -> Q (in EDMD2; dbSNP:rs58105277)"
FT                   /evidence="ECO:0000269|PubMed:10739764,
FT                   ECO:0000269|PubMed:12467752"
FT                   /id="VAR_009983"
FT   VARIANT         343
FT                   /note="R -> Q (in EDMD2; dbSNP:rs61177390)"
FT                   /evidence="ECO:0000269|PubMed:12467752"
FT                   /id="VAR_009984"
FT   VARIANT         349
FT                   /note="R -> L (in CMD1A; dbSNP:rs58789393)"
FT                   /evidence="ECO:0000269|PubMed:15219508"
FT                   /id="VAR_039776"
FT   VARIANT         355
FT                   /note="Missing (in EDMD2)"
FT                   /evidence="ECO:0000269|PubMed:20848652"
FT                   /id="VAR_064969"
FT   VARIANT         358
FT                   /note="E -> K (in EDMD2 and MDCL; aberrant localization
FT                   with decreased nuclear rim staining and formation of
FT                   intranuclear foci when transfected in C2C12 myoblasts; no
FT                   obvious effect on nuclear morphology in cultured skin
FT                   fibroblasts from heterozygous patients; distribution of
FT                   endogenous LMNA, LMNB1 and LMNB2 are altered in cells
FT                   expressing this mutant; interacts with itself and with
FT                   wild-type LMNA and LMNB1; no effect on protein level;
FT                   dbSNP:rs60458016)"
FT                   /evidence="ECO:0000269|PubMed:10939567,
FT                   ECO:0000269|PubMed:11503164, ECO:0000269|PubMed:11792809,
FT                   ECO:0000269|PubMed:15372542, ECO:0000269|PubMed:18551513,
FT                   ECO:0000269|PubMed:20848652"
FT                   /id="VAR_009985"
FT   VARIANT         361
FT                   /note="E -> K (in EDMD2; dbSNP:rs267607634)"
FT                   /evidence="ECO:0000269|PubMed:20848652"
FT                   /id="VAR_064970"
FT   VARIANT         371
FT                   /note="M -> K (in EDMD2; dramatically aberrant localization
FT                   with decreased nuclear rim staining and formation of
FT                   intranuclear foci; distribution of endogenous LMNA, LMNB1
FT                   and LMNB2 are altered in cells expressing this mutant;
FT                   causes an increased loss of endogenous EMD from the nuclear
FT                   envelope; interacts with itself and with wild-type LMNA and
FT                   LMNB1; no decrease in the stability compared with
FT                   wild-type; dbSNP:rs59653062)"
FT                   /evidence="ECO:0000269|PubMed:10939567,
FT                   ECO:0000269|PubMed:11792809"
FT                   /id="VAR_009986"
FT   VARIANT         377
FT                   /note="R -> H (in EDMD2; no obvious effect on nuclear
FT                   morphology in cultured skin fibroblasts from heterozygous
FT                   patients; no effect on protein level; dbSNP:rs61672878)"
FT                   /evidence="ECO:0000269|PubMed:10814726,
FT                   ECO:0000269|PubMed:12628721, ECO:0000269|PubMed:12673789,
FT                   ECO:0000269|PubMed:15372542, ECO:0000269|PubMed:15744034,
FT                   ECO:0000269|PubMed:17136397"
FT                   /id="VAR_016205"
FT   VARIANT         377
FT                   /note="R -> L (in EDMD2; dbSNP:rs61672878)"
FT                   /evidence="ECO:0000269|PubMed:12032588,
FT                   ECO:0000269|PubMed:12649505"
FT                   /id="VAR_039777"
FT   VARIANT         380
FT                   /note="L -> S (in MDCL; dbSNP:rs121912495)"
FT                   /evidence="ECO:0000269|PubMed:18551513"
FT                   /id="VAR_063591"
FT   VARIANT         386
FT                   /note="R -> K (in EDMD2; dramatically aberrant localization
FT                   with decreased nuclear rim staining and formation of
FT                   intranuclear foci; distribution of endogenous LMNA, LMNB1
FT                   and LMNB2 are altered in cells expressing this mutant;
FT                   causes an increased loss of endogenous EMD from the nuclear
FT                   envelope; interacts with itself and with wild-type LMNA and
FT                   LMNB1; no decrease in the stability compared with
FT                   wild-type; dbSNP:rs267607545)"
FT                   /evidence="ECO:0000269|PubMed:10939567,
FT                   ECO:0000269|PubMed:11792809, ECO:0000269|PubMed:12649505,
FT                   ECO:0000269|PubMed:20848652"
FT                   /id="VAR_009987"
FT   VARIANT         388
FT                   /note="R -> H (in CMD1A; no effect on nuclear morphology
FT                   but restricts lamin A to the cytoplasm; dbSNP:rs267607576)"
FT                   /evidence="ECO:0000269|PubMed:20160190"
FT                   /id="VAR_070180"
FT   VARIANT         399
FT                   /note="R -> C (in FPLD2 and CMD1A; no effect on nuclear
FT                   morphology and lamin A localization; dbSNP:rs58672172)"
FT                   /evidence="ECO:0000269|PubMed:17250669,
FT                   ECO:0000269|PubMed:20160190"
FT                   /id="VAR_039778"
FT   VARIANT         401
FT                   /note="R -> C (in EDMD2; abnormal nuclear localization in a
FT                   honeycomb expression pattern in about 22% of cultured skin
FT                   fibroblasts from heterozygous patients; enhances the
FT                   interaction with SYNE2; no effect on nuclear localization;
FT                   no effect on protein level; dbSNP:rs61094188)"
FT                   /evidence="ECO:0000269|PubMed:12467752,
FT                   ECO:0000269|PubMed:15372542, ECO:0000269|PubMed:23977161"
FT                   /id="VAR_072818"
FT   VARIANT         411
FT                   /note="G -> D (probable disease-associated variant found in
FT                   patients with metabolic syndromes; no effect on nuclear
FT                   lamin A localization; no effect on the interaction with
FT                   SYNE2; dbSNP:rs267607647)"
FT                   /evidence="ECO:0000269|PubMed:21724554,
FT                   ECO:0000269|PubMed:23977161"
FT                   /id="VAR_072819"
FT   VARIANT         413
FT                   /note="G -> C (found in patients with skeletal and cardiac
FT                   muscular dystrophies; no effect on nuclear lamin A
FT                   localization; no effect on the interaction with SYNE2;
FT                   dbSNP:rs766811975)"
FT                   /evidence="ECO:0000269|PubMed:23977161"
FT                   /id="VAR_072820"
FT   VARIANT         415
FT                   /note="V -> I (rare variant; found in patients with atrial
FT                   fibrillation; unknown pathological significance; no effect
FT                   on nuclear lamin A localization; enhances the interaction
FT                   with SYNE2; causes nuclear deformations in heat shock
FT                   experiments; dbSNP:rs267607606)"
FT                   /evidence="ECO:0000269|PubMed:19427440,
FT                   ECO:0000269|PubMed:23977161"
FT                   /id="VAR_072821"
FT   VARIANT         419
FT                   /note="R -> C (found in patients with lipodystrophy; no
FT                   effect on nuclear lamin A localization; no effect on the
FT                   interaction with SYNE2; dbSNP:rs755686359)"
FT                   /evidence="ECO:0000269|PubMed:23977161"
FT                   /id="VAR_072822"
FT   VARIANT         421
FT                   /note="L -> P (probable disease-associated variant found in
FT                   patient with severe metabolic syndrome; no effect on
FT                   nuclear lamin A localization; no effect on the interaction
FT                   with SYNE2; dbSNP:rs267607564)"
FT                   /evidence="ECO:0000269|PubMed:17711925,
FT                   ECO:0000269|PubMed:23977161"
FT                   /id="VAR_072823"
FT   VARIANT         427
FT                   /note="R -> G (found in patients with skeletal and cardiac
FT                   muscular dystrophies; unknown pathological significance; no
FT                   effect on nuclear lamin A localization; no effect on the
FT                   interaction with SYNE2)"
FT                   /evidence="ECO:0000269|PubMed:23977161"
FT                   /id="VAR_072824"
FT   VARIANT         435
FT                   /note="R -> C (in CMD1A; dbSNP:rs150840924)"
FT                   /evidence="ECO:0000269|PubMed:14684700"
FT                   /id="VAR_039779"
FT   VARIANT         439
FT                   /note="R -> C (in FPLD2; increase in nuclear blebbing and
FT                   formation of honeycomb-like structures in the nuclei with
FT                   no accumulation of prelamin A in skin fibroblasts; causes
FT                   oligomerization of the C-terminal globular domain of lamins
FT                   A and C under no-reducing conditions and increases binding
FT                   affinity for DNA; increases sensitivity to oxidative
FT                   stress; no significant differences in stability and
FT                   structure compared with the wild-type; dbSNP:rs62636506)"
FT                   /evidence="ECO:0000269|PubMed:19220582"
FT                   /id="VAR_070181"
FT   VARIANT         446
FT                   /note="D -> V (in EDMD2; dbSNP:rs58541611)"
FT                   /evidence="ECO:0000269|PubMed:14684700"
FT                   /id="VAR_039780"
FT   VARIANT         449
FT                   /note="G -> D (in EDMD2; dbSNP:rs267607637)"
FT                   /evidence="ECO:0000269|PubMed:20848652"
FT                   /id="VAR_064971"
FT   VARIANT         453
FT                   /note="R -> P (in MDCL; dbSNP:rs267607598)"
FT                   /evidence="ECO:0000269|PubMed:18551513"
FT                   /id="VAR_063592"
FT   VARIANT         453
FT                   /note="R -> W (in EDMD2; abnormal nuclear localization;
FT                   forms nuclear foci in about 8% of cultured skin fibroblasts
FT                   from heterozygous patients; interacts with itself and with
FT                   wild-type LMNA and LMNB1; no effect on protein level;
FT                   dbSNP:rs58932704)"
FT                   /evidence="ECO:0000269|PubMed:10080180,
FT                   ECO:0000269|PubMed:10739764, ECO:0000269|PubMed:10939567,
FT                   ECO:0000269|PubMed:11503164, ECO:0000269|PubMed:11792809,
FT                   ECO:0000269|PubMed:14684700, ECO:0000269|PubMed:15372542,
FT                   ECO:0000269|PubMed:20848652"
FT                   /id="VAR_009988"
FT   VARIANT         454
FT                   /note="L -> P (in EDMD2; dbSNP:rs267607638)"
FT                   /evidence="ECO:0000269|PubMed:20848652"
FT                   /id="VAR_064972"
FT   VARIANT         455
FT                   /note="R -> P (in MDCL; dbSNP:rs267607597)"
FT                   /evidence="ECO:0000269|PubMed:18551513"
FT                   /id="VAR_063593"
FT   VARIANT         456
FT                   /note="N -> D (in MDCL; dbSNP:rs267607599)"
FT                   /evidence="ECO:0000269|PubMed:18551513"
FT                   /id="VAR_063594"
FT   VARIANT         456
FT                   /note="N -> I (in EDMD2; mislocalized in the nucleus; does
FT                   not alter nuclear size or shape; dbSNP:rs60992550)"
FT                   /evidence="ECO:0000269|PubMed:11503164,
FT                   ECO:0000269|PubMed:20848652"
FT                   /id="VAR_039781"
FT   VARIANT         456
FT                   /note="N -> K (in EDMD2; dbSNP:rs61235244)"
FT                   /evidence="ECO:0000269|PubMed:10939567"
FT                   /id="VAR_039782"
FT   VARIANT         461
FT                   /note="D -> Y (in EDMD2; dbSNP:rs267607642)"
FT                   /evidence="ECO:0000269|PubMed:20848652"
FT                   /id="VAR_064973"
FT   VARIANT         465
FT                   /note="G -> D (in FPLD2; dbSNP:rs61282106)"
FT                   /evidence="ECO:0000269|PubMed:10739751"
FT                   /id="VAR_009989"
FT   VARIANT         467
FT                   /note="W -> R (in EDMD2; dbSNP:rs267607639)"
FT                   /evidence="ECO:0000269|PubMed:20848652"
FT                   /id="VAR_064974"
FT   VARIANT         469
FT                   /note="I -> T (in EDMD2; dbSNP:rs57394692)"
FT                   /evidence="ECO:0000269|PubMed:10739764"
FT                   /id="VAR_009990"
FT   VARIANT         471
FT                   /note="R -> C (in HGPS; dbSNP:rs28928902)"
FT                   /evidence="ECO:0000269|PubMed:12768443"
FT                   /id="VAR_017662"
FT   VARIANT         471
FT                   /note="R -> H (in CMD1A; no effect on nuclear morphology
FT                   and lamin A localization; dbSNP:rs267607578)"
FT                   /evidence="ECO:0000269|PubMed:20160190"
FT                   /id="VAR_070182"
FT   VARIANT         481
FT                   /note="Y -> H (in EDMD2; dbSNP:rs57747780)"
FT                   /evidence="ECO:0000269|PubMed:11525883"
FT                   /id="VAR_039783"
FT   VARIANT         482
FT                   /note="R -> L (in FPLD2; abnormal nuclear localization in a
FT                   honeycomb expression pattern in about 10% of cultured skin
FT                   fibroblasts from heterozygous patients; no effect on
FT                   protein level; dbSNP:rs11575937)"
FT                   /evidence="ECO:0000269|PubMed:10655060,
FT                   ECO:0000269|PubMed:15372542"
FT                   /id="VAR_009991"
FT   VARIANT         482
FT                   /note="R -> Q (in FPLD2; interacts with itself and with
FT                   wild-type LMNA and LMNB1; no decrease in the stability
FT                   compared with wild-type; dbSNP:rs11575937)"
FT                   /evidence="ECO:0000269|PubMed:10587585,
FT                   ECO:0000269|PubMed:10739751, ECO:0000269|PubMed:11792809"
FT                   /id="VAR_009992"
FT   VARIANT         482
FT                   /note="R -> W (in FPLD2; interacts with itself and with
FT                   wild-type LMNA and LMNB1; no decrease in the stability
FT                   compared with wild-type; decreases binding affinity for
FT                   DNA; increases sensitivity to oxidative stress;
FT                   dbSNP:rs57920071)"
FT                   /evidence="ECO:0000269|PubMed:10655060,
FT                   ECO:0000269|PubMed:10739751, ECO:0000269|PubMed:11792809,
FT                   ECO:0000269|PubMed:19220582"
FT                   /id="VAR_009993"
FT   VARIANT         486
FT                   /note="K -> N (in FPLD2; interacts with itself and with
FT                   wild-type LMNA and LMNB1; no decrease in the stability
FT                   compared with wild-type; dbSNP:rs59981161)"
FT                   /evidence="ECO:0000269|PubMed:11792809"
FT                   /id="VAR_009994"
FT   VARIANT         488
FT                   /note="T -> P (found in patient with atrial fibrillation;
FT                   dbSNP:rs267607607)"
FT                   /evidence="ECO:0000269|PubMed:19427440"
FT                   /id="VAR_072825"
FT   VARIANT         515
FT                   /note="K -> E (in FPLD2)"
FT                   /evidence="ECO:0000269|PubMed:24485160"
FT                   /id="VAR_071968"
FT   VARIANT         520
FT                   /note="W -> S (in EDMD2; interacts with itself and with
FT                   wild-type LMNA and LMNB1; no decrease in the stability
FT                   compared with wild-type; dbSNP:rs58362413)"
FT                   /evidence="ECO:0000269|PubMed:10939567,
FT                   ECO:0000269|PubMed:11792809"
FT                   /id="VAR_039784"
FT   VARIANT         523
FT                   /note="G -> R (in CMD1A; unknown pathological significance;
FT                   dbSNP:rs201583907)"
FT                   /evidence="ECO:0000269|PubMed:21846512"
FT                   /id="VAR_067258"
FT   VARIANT         527
FT                   /note="R -> C (in HGPS; dbSNP:rs57318642)"
FT                   /evidence="ECO:0000269|PubMed:12768443"
FT                   /id="VAR_017663"
FT   VARIANT         527
FT                   /note="R -> H (in MADA; dbSNP:rs57520892)"
FT                   /evidence="ECO:0000269|PubMed:12075506"
FT                   /id="VAR_018727"
FT   VARIANT         527
FT                   /note="R -> P (in EDMD2 and FPLD2; interacts with itself
FT                   and with wild-type LMNA and LMNB1; reduced binding to SUN1;
FT                   abnormal nuclear localization; forms nuclear foci in about
FT                   13% of cultured skin fibroblasts from heterozygous
FT                   patients; no effect on protein level; dbSNP:rs57520892)"
FT                   /evidence="ECO:0000269|PubMed:10080180,
FT                   ECO:0000269|PubMed:10739764, ECO:0000269|PubMed:10939567,
FT                   ECO:0000269|PubMed:11503164, ECO:0000269|PubMed:11792809,
FT                   ECO:0000269|PubMed:12196663, ECO:0000269|PubMed:12649505,
FT                   ECO:0000269|PubMed:15372542, ECO:0000269|PubMed:15744034,
FT                   ECO:0000269|PubMed:19933576, ECO:0000269|PubMed:20848652"
FT                   /id="VAR_009995"
FT   VARIANT         528
FT                   /note="T -> K (in EDMD2; interacts with itself and with
FT                   wild-type LMNA and LMNB1; no decrease in the stability
FT                   compared with wild-type; dbSNP:rs57629361)"
FT                   /evidence="ECO:0000269|PubMed:10739764,
FT                   ECO:0000269|PubMed:10939567, ECO:0000269|PubMed:11792809,
FT                   ECO:0000269|PubMed:20848652"
FT                   /id="VAR_009996"
FT   VARIANT         528
FT                   /note="T -> R (in EDMD2; dbSNP:rs57629361)"
FT                   /evidence="ECO:0000269|PubMed:14684700,
FT                   ECO:0000269|PubMed:20848652"
FT                   /id="VAR_039785"
FT   VARIANT         529
FT                   /note="A -> V (in MADA; dbSNP:rs60580541)"
FT                   /evidence="ECO:0000269|PubMed:15998779"
FT                   /id="VAR_034709"
FT   VARIANT         530
FT                   /note="L -> P (in EDMD2; interacts with itself and with
FT                   wild-type LMNA and LMNB1; reduced binding to SUN1; no
FT                   decrease in the stability compared with wild-type;
FT                   dbSNP:rs60934003)"
FT                   /evidence="ECO:0000269|PubMed:10080180,
FT                   ECO:0000269|PubMed:11792809, ECO:0000269|PubMed:19933576"
FT                   /id="VAR_009997"
FT   VARIANT         541
FT                   /note="R -> C (in CMD1A; grossly abnormal nuclear shape
FT                   with the nuclear envelope producing prominent lobules in
FT                   about 10% of cultured skin fibroblasts from heterozygous
FT                   patients; dbSNP:rs56984562)"
FT                   /evidence="ECO:0000269|PubMed:14675861,
FT                   ECO:0000269|PubMed:15372542, ECO:0000269|PubMed:19167105"
FT                   /id="VAR_039786"
FT   VARIANT         541
FT                   /note="R -> H (in EDMD2; dbSNP:rs61444459)"
FT                   /evidence="ECO:0000269|PubMed:14684700"
FT                   /id="VAR_039787"
FT   VARIANT         541
FT                   /note="R -> P (in EDMD2; mis-localized in the nucleus; does
FT                   not alter nuclear size or shape; dbSNP:rs61444459)"
FT                   /evidence="ECO:0000269|PubMed:20848652"
FT                   /id="VAR_064975"
FT   VARIANT         541
FT                   /note="R -> S (in EDMD2 and CMD1A; modest and non-specific
FT                   nuclear membrane alterations; the phenotype is entirely
FT                   reversed by coexpression of the S-541 mutation and
FT                   wild-type lamin-C; dbSNP:rs56984562)"
FT                   /evidence="ECO:0000269|PubMed:16061563,
FT                   ECO:0000269|PubMed:20848652"
FT                   /id="VAR_039788"
FT   VARIANT         542
FT                   /note="K -> N (in HGPS; dbSNP:rs56673169)"
FT                   /evidence="ECO:0000269|PubMed:15286156"
FT                   /id="VAR_034710"
FT   VARIANT         573
FT                   /note="S -> L (in CMD1A, FPLD2 and MADA; dbSNP:rs60890628)"
FT                   /evidence="ECO:0000269|PubMed:12628721,
FT                   ECO:0000269|PubMed:16278265, ECO:0000269|PubMed:17250669"
FT                   /id="VAR_039789"
FT   VARIANT         578
FT                   /note="E -> V (in an atypical progeroid patient; diagnosed
FT                   as Werner syndrome; dbSNP:rs61224243)"
FT                   /evidence="ECO:0000269|PubMed:15060110"
FT                   /id="VAR_039790"
FT   VARIANT         582
FT                   /note="R -> H (in FPLD2; dbSNP:rs57830985)"
FT                   /evidence="ECO:0000269|PubMed:10739751"
FT                   /id="VAR_009998"
FT   VARIANT         602
FT                   /note="G -> S (in EDMD2; dbSNP:rs60662302)"
FT                   /evidence="ECO:0000269|PubMed:20848652"
FT                   /id="VAR_064976"
FT   VARIANT         608
FT                   /note="G -> S (in HGPS; reduced binding to SUN1; may affect
FT                   splicing by activating a cryptic splice donor site;
FT                   dbSNP:rs61064130)"
FT                   /evidence="ECO:0000269|PubMed:12714972,
FT                   ECO:0000269|PubMed:12768443, ECO:0000269|PubMed:19933576"
FT                   /id="VAR_017664"
FT   VARIANT         624
FT                   /note="R -> H (in EDMD2; dbSNP:rs13768)"
FT                   /evidence="ECO:0000269|PubMed:11503164"
FT                   /id="VAR_039791"
FT   VARIANT         631
FT                   /note="G -> D (probable disease-associated variant found in
FT                   a patient with metabolic syndrome; dbSNP:rs267607648)"
FT                   /evidence="ECO:0000269|PubMed:21724554"
FT                   /id="VAR_072826"
FT   VARIANT         644
FT                   /note="R -> C (in HGPS and EDMD2; unknown pathological
FT                   significance; partially inhibits tail cleavage;
FT                   dbSNP:rs142000963)"
FT                   /evidence="ECO:0000269|PubMed:15060110,
FT                   ECO:0000269|PubMed:20848652, ECO:0000269|PubMed:22355414"
FT                   /id="VAR_039792"
FT   MUTAGEN         22
FT                   /note="S->A: Decreased accumulation to the double-strand
FT                   break (DSB) sites."
FT                   /evidence="ECO:0000269|PubMed:31548606"
FT   MUTAGEN         22
FT                   /note="S->D: Increased accumulation to the double-strand
FT                   break (DSB) sites."
FT                   /evidence="ECO:0000269|PubMed:31548606"
FT   MUTAGEN         201
FT                   /note="K->L: Decreased sumoylation; aberrant localization
FT                   with decreased nuclear rim staining and formation of
FT                   intranuclear foci; associated with increased cell death."
FT                   /evidence="ECO:0000269|PubMed:18606848"
FT   MUTAGEN         358
FT                   /note="E->K: Loss of interaction with IFFO1."
FT                   /evidence="ECO:0000269|PubMed:31548606"
FT   MUTAGEN         386
FT                   /note="R->M: Loss of interaction with IFFO1."
FT                   /evidence="ECO:0000269|PubMed:31548606"
FT   MUTAGEN         644
FT                   /note="R->A: Does not affect tail cleavage."
FT                   /evidence="ECO:0000269|PubMed:22355414"
FT   MUTAGEN         647
FT                   /note="L->R: Completely inhibits tail cleavage."
FT                   /evidence="ECO:0000269|PubMed:22355414"
FT   MUTAGEN         648
FT                   /note="L->A: Completely inhibits tail cleavage."
FT                   /evidence="ECO:0000269|PubMed:22355414"
FT   MUTAGEN         650
FT                   /note="N->A: Partially inhibits tail cleavage."
FT                   /evidence="ECO:0000269|PubMed:22355414"
FT   MUTAGEN         661
FT                   /note="C->S: Loss of interaction with NARF. Abolishes
FT                   farnesylation."
FT                   /evidence="ECO:0000269|PubMed:10514485,
FT                   ECO:0000269|PubMed:22355414"
FT   CONFLICT        340
FT                   /note="E -> K (in Ref. 5; BAG58344)"
FT                   /evidence="ECO:0000305"
FT   STRAND          20..22
FT                   /evidence="ECO:0007829|PDB:6YF5"
FT   STRAND          25..27
FT                   /evidence="ECO:0007829|PDB:6YF5"
FT   HELIX           28..70
FT                   /evidence="ECO:0007829|PDB:6YF5"
FT   HELIX           252..278
FT                   /evidence="ECO:0007829|PDB:6JLB"
FT   HELIX           316..384
FT                   /evidence="ECO:0007829|PDB:1X8Y"
FT   STRAND          430..436
FT                   /evidence="ECO:0007829|PDB:7Z21"
FT   STRAND          438..445
FT                   /evidence="ECO:0007829|PDB:1IFR"
FT   STRAND          449..456
FT                   /evidence="ECO:0007829|PDB:1IFR"
FT   STRAND          458..460
FT                   /evidence="ECO:0007829|PDB:1IFR"
FT   HELIX           464..466
FT                   /evidence="ECO:0007829|PDB:1IVT"
FT   STRAND          468..473
FT                   /evidence="ECO:0007829|PDB:1IFR"
FT   STRAND          479..482
FT                   /evidence="ECO:0007829|PDB:1IFR"
FT   STRAND          494..499
FT                   /evidence="ECO:0007829|PDB:1IFR"
FT   HELIX           500..502
FT                   /evidence="ECO:0007829|PDB:3GEF"
FT   TURN            508..510
FT                   /evidence="ECO:0007829|PDB:1IFR"
FT   STRAND          511..514
FT                   /evidence="ECO:0007829|PDB:1IFR"
FT   STRAND          526..531
FT                   /evidence="ECO:0007829|PDB:1IFR"
FT   STRAND          537..543
FT                   /evidence="ECO:0007829|PDB:1IFR"
FT   CONFLICT        P02545-4:556
FT                   /note="G -> R (in Ref. 5; BAG58344)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   664 AA;  74139 MW;  E0855F7699F0318B CRC64;
     METPSQRRAT RSGAQASSTP LSPTRITRLQ EKEDLQELND RLAVYIDRVR SLETENAGLR
     LRITESEEVV SREVSGIKAA YEAELGDARK TLDSVAKERA RLQLELSKVR EEFKELKARN
     TKKEGDLIAA QARLKDLEAL LNSKEAALST ALSEKRTLEG ELHDLRGQVA KLEAALGEAK
     KQLQDEMLRR VDAENRLQTM KEELDFQKNI YSEELRETKR RHETRLVEID NGKQREFESR
     LADALQELRA QHEDQVEQYK KELEKTYSAK LDNARQSAER NSNLVGAAHE ELQQSRIRID
     SLSAQLSQLQ KQLAAKEAKL RDLEDSLARE RDTSRRLLAE KEREMAEMRA RMQQQLDEYQ
     ELLDIKLALD MEIHAYRKLL EGEEERLRLS PSPTSQRSRG RASSHSSQTQ GGGSVTKKRK
     LESTESRSSF SQHARTSGRV AVEEVDEEGK FVRLRNKSNE DQSMGNWQIK RQNGDDPLLT
     YRFPPKFTLK AGQVVTIWAA GAGATHSPPT DLVWKAQNTW GCGNSLRTAL INSTGEEVAM
     RKLVRSVTVV EDDEDEDGDD LLHHHHGSHC SSSGDPAEYN LRSRTVLCGT CGQPADKASA
     SGSGAQVGGP ISSGSSASSV TVTRSYRSVG GSGGGSFGDN LVTRSYLLGN SSPRTQSPQN
     CSIM
//
